Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Bonaventura Clotet

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

HIV Infections

Living Beings

HIV-1

Chemicals & Drugs

Procedures

Concepts & Ideas

Physiology

Anatomy

CD4-Positive T-Lymphocytes

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Pérez-Elías María J; Morellon María Larrousse; Ortega Enrique; Hernández-Quero José; Rodríguez-Torres Maribel; Clotet Bonaventura; Felizarta Franco; Gutiérrez Felix; Pineda Juan A; Nichols Garrett; Lou Yu; Wire Mary Beth
Pharmacokinetics of Fosamprenavir plus Ritonavir in Human Immunodeficiency Virus Type 1-Infected Adult Subjects with Hepatic Impairment.
Fumaz Carmina R; Gonzalez-Garcia Marian; Borras Xavier; Ferrer Maria Jose; Muñoz-Moreno Jose A; Peña Ruth; Perez-Alvarez Nuria; Puig Jordi; Paredes Roger; Fernandez-Castro Jordi; Clotet Bonaventura
Increased peripheral proinflammatory cytokines in HIV-1-infected patients with prolonged viral suppression suffering from high psychological stress.
Negredo Eugenia; Miró Oscar; Rodríguez-Santiago Benjamí; Garrabou Glòria; Estany Carla; Masabeu Angels; Force Lluís; Barrufet Pilar; Cucurull Josep; Domingo Pere; Alonso-Villaverde Carlos; Bonjoch Anna; Morén Constanza; Pérez-Alvarez Núria; Clotet Bonaventura;
Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Bonaventura Clotet (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Pérez-Elías María J; Morellon María Larrousse; Ortega Enrique; Hernández-Quero José; Rodríguez-Torres Maribel; Clotet Bonaventura; Felizarta Franco; Gutiérrez Felix; Pineda Juan A; Nichols Garrett; Lou Yu; Wire Mary Beth
Pharmacokinetics of Fosamprenavir plus Ritonavir in Human Immunodeficiency Virus Type 1-Infected Adult Subjects with Hepatic Impairment.
Antimicrobial agents and chemotherapy 2009;53(12):5185-96.
2009: Fumaz Carmina R; Gonzalez-Garcia Marian; Borras Xavier; Ferrer Maria Jose; Muñoz-Moreno Jose A; Peña Ruth; Perez-Alvarez Nuria; Puig Jordi; Paredes Roger; Fernandez-Castro Jordi; Clotet Bonaventura
Increased peripheral proinflammatory cytokines in HIV-1-infected patients with prolonged viral suppression suffering from high psychological stress.
Journal of acquired immune deficiency syndromes (1999) 2009;52(3):427-8.
2009: Negredo Eugenia; Miró Oscar; Rodríguez-Santiago Benjamí; Garrabou Glòria; Estany Carla; Masabeu Angels; Force Lluís; Barrufet Pilar; Cucurull Josep; Domingo Pere; Alonso-Villaverde Carlos; Bonjoch Anna; Morén Constanza; Pérez-Alvarez Núria; Clotet Bonaventura;
Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;49(6):892-900.
2009: Parera Mariona; Perez-Alvarez Nuria; Clotet Bonaventura; Martínez Miguel Angel
Epistasis among deleterious mutations in the HIV-1 protease.
Journal of molecular biology 2009;392(2):243-50.
2009: Cozzi-Lepri Alessandro; Phillips Andrew N; Martinez-Picado Javier; Monforte Antonella d'Arminio; Katlama Christine; Eg Hansen Ann-Brit; Horban Andrzej; Bruun Johann; Clotet Bonaventura; Lundgren Jens D;
Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.
The Journal of infectious diseases 2009;200(5):687-97.
2009: Puertas Maria Carmen; Buzón Maria Jose; Artese Anna; Alcaro Stefano; Menendez-Arias Luis; Perno Carlo Federico; Clotet Bonaventura; Ceccherini-Silberstein Francesca; Martinez-Picado Javier
Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility.
Journal of virology 2009;83(15):7434-9.
2009: Pérez-Elías María Jesús; Gatell Jose María; Flores Juan; Santos Jesús; Vera-Médez Francisco; Clotet Bonaventura; Moreno Ana; Pérez-Molina Jose-Antonio; Vendrell Belén; Serrano Oscar
Short-term effect of ritonavir-boosted atazanavir in hepatitis B and/or C co-infected, treatment-experienced HIV patients.
HIV clinical trials 2009;10(4):269-75.
2009: Llibre Josep M; Falco Vicenç; Tural Cristina; Negredo Eugenia; Pineda Juan A; Muñoz Jose; Ortega Enrique; Videla Sebastia; Sirera Guillem; Martinez Esteban; Miralles Celia; Iribarren Josean; Galindo Maria J; Domingo Pere; d'Arminio-Monforte Antonella; Miro Jose M; Clotet Bonaventura
The changing face of HIV/AIDS in treated patients.
Current HIV research 2009;7(4):365-77.
2009: Heras Eva; Llibre Josep M; Sirera Guillem; Mate Jose L; Boix Vicente; Rey-Joly Celestino; Clotet Bonaventura
Lymphogranuloma venerium proctitis in the setting of HIV: a case report and differential diagnosis.
AIDS patient care and STDs 2009;23(7):493-4.
2009: Clotet-Codina Imma; Bosch Berta; Senserrich Jordi; Fernández-Figueras María Teresa; Peña Ruth; Ballana Ester; Bofill Margarita; Clotet Bonaventura; Esté José A
HIV endocytosis after dendritic cell to T cell viral transfer leads to productive virus infection.
Antiviral research 2009;83(1):94-8.
2009: Martínez Esteban; Arranz José A; Podzamczer Daniel; Loncá Montserrat; Sanz José; Barragán Patricia; Ribera Esteban; Knobel Hernando; Roca Victor; Gutiérrez Félix; Blanco José L; Mallolas Josep; Llibre Josep M; Clotet Bonaventura; Dalmau David; Segura Ferran; Arribas José R; Cosín Jaime; Barrufet Pilar; Casas Esperanza; Ferrer Elena; Curran Adrià; González Alicia; Pich Judit; Cruceta Ana; Arnaiz Joan A; Miró José M; Gatell José M;
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
Journal of acquired immune deficiency syndromes (1999) 2009;51(3):290-7.
2009: Sanvisens A; Serra I; Tural C; Tor J; Ojanguren I; Barluenga E; Rey-Joly C; Clotet B; Muga R
Hyaluronic acid, transforming growth factor-beta1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co-infection.
Journal of viral hepatitis 2009;16(7):513-8.
2009: Fumaz Carmina R; Muñoz-Moreno Jose A; Ferrer María José; Negredo Eugenia; Pérez-Alvarez Núria; Tarrats Antoni; Clotet Bonaventura
Low levels of adherence to antiretroviral therapy in HIV-1-infected women with menstrual disorders.
AIDS patient care and STDs 2009;23(6):463-8.
2009: Murphy Robert L; Autran Brigitte; Katlama Christine; Brucker Gilles; Debre Patrice; Calvez Vincent; Clotet Bonaventura; Clumeck Nathan; Costagliola Dominique; Deeks Steven G; Dorrell Lucy; Gatell Jose; Haase Ashley; Klein Michel; Lazzarin Adriano; McMichael Andrew J; Papagno Laura; Schacker Timothy W; Wain-Hobson Simon; Walker Bruce D; Youle Michael
A step ahead on the HIV collaboratory.
Science (New York, N.Y.) 2009;324(5932):1264-5.
2009: Saag Michael; Goodrich James; Fätkenheuer Gerd; Clotet Bonaventura; Clumeck Nathan; Sullivan John; Westby Mike; van der Ryst Elna; Mayer Howard;
A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.
The Journal of infectious diseases 2009;199(11):1638-47.
2009: Santos José Ramón; Moltó José; Llibre Josep Maria; Pérez Nuria; Capitán; Miranda Cristina; Clotet Bonaventura
Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.
HIV clinical trials 2009;10(3):129-34.
2009: Mallolas Josep; Podzamczer Daniel; Milinkovic Ana; Domingo Pere; Clotet Bonaventura; Ribera Esteve; Gutiérrez Félix; Knobel Hernando; Cosin Jaime; Ferrer Elena; Arranz José Alberto; Roca Victor; Vidal Francesc; Murillas Javier; Pich Judit; Pedrol Enric; Llibre Josep M; Dalmau David; García Isabel; Aranda Miquel; Cruceta Ana; Martínez Esteban; Blanco José L; Lazzari Elisa de; Gatell José M;
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.
Journal of acquired immune deficiency syndromes (1999) 2009;51(1):29-36.
2009: Moltó José; Llibre Josep Maria; Ribera Esteban; Mínguez Carlos; del Río Jesús Sánchez; Pedrol Enric; Vallecillo Gabriel; Cedeño Samandhy; Valle Marta; Miranda Cristina; Negredo Eugenia; Clotet Bonaventura;
Saquinavir exposure in HIV-infected patients with chronic viral hepatitis.
The Journal of antimicrobial chemotherapy 2009;63(5):992-7.
2009: Pruvost Alain; Negredo Eugènia; Théodoro Frédéric; Puig Jordi; Levi Mikaël; Ayen Rafaela; Grassi Jacques; Clotet Bonaventura
Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
Antimicrobial agents and chemotherapy 2009;53(5):1937-43.
2009: Muñoz-Moreno José A; Fumaz Carmina R; Ferrer Maria J; González-García Marian; Moltó José; Negredo Eugènia; Clotet Bonaventura
Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review.
AIDS reviews 2009;11(2):103-9.
2009: Negredo Eugenia; Puig Jordi; Aldea David; Medina Manuel; Estany Carla; Pérez-Alvarez Núria; Rodríguez-Fumaz Carmina; Muñoz-Moreno Jose A; Higueras Carmen; Gonzalez-Mestre Vicente; Clotet Bonaventura
Four-year safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophy.
AIDS research and human retroviruses 2009;25(4):451-5.
2009: Minuesa Gerard; Volk Christopher; Molina-Arcas Míriam; Gorboulev Valentin; Erkizia Itziar; Arndt Petra; Clotet Bonaventura; Pastor-Anglada Marçal; Koepsell Hermann; Martinez-Picado Javier
Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3.
The Journal of pharmacology and experimental therapeutics 2009;329(1):252-61.
2009: Harris Marianne; Côté Hélène; Ochoa Claudia; Allavena Clotilde; Negredo Eugenia; Thorne Anona; Cahn Pedro; Zala Carlos; Raffi Francois; Clotet Bonaventura; Singer Joel; Montaner Julio;
A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients.
Journal of acquired immune deficiency syndromes (1999) 2009;50(3):335-7.
2009: Tural Cristina; Tor Jordi; Sanvisens Arantza; Pérez-Alvarez Núria; Martínez Elisenda; Ojanguren Isabel; García-Samaniego Javier; Rockstroh Juergen; Barluenga Eva; Muga Robert; Planas Ramon; Sirera Guillem; Rey-Joly Celestino; Clotet Bonaventura
Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2009;7(3):339-45.
2009: Izquierdo-Useros Nuria; Naranjo-Gómez Mar; Archer Jacob; Hatch Steven C; Erkizia Itziar; Blanco Julià; Borràs Francesc E; Puertas Maria Carmen; Connor John H; Fernández-Figueras Maria Teresa; Moore Landon; Clotet Bonaventura; Gummuluru Suryaram; Martinez-Picado Javier
Capture and transfer of HIV-1 particles by mature dendritic cells converges with the exosome-dissemination pathway.
Blood 2009;113(12):2732-41.
2009: Darwich Laila; Coma Gemma; Peña Ruth; Bellido Rocio; Blanco Ester J J; Este José A; Borras Francesc E; Clotet Bonaventura; Ruiz Lidia; Rosell Antoni; Andreo Felipe; Parkhouse R Michael E; Bofill Margarita
Secretion of interferon-gamma by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18.
Immunology 2009;126(3):386-93.
2009: Videla Sebastian; Darwich Laila; Cañadas Maria Paz; Paredes Roger; Tarrats Antoni; Castella Eva; Llatjos Mariona; Bofill Margarita; Clotet Bonaventura; Sirera Guillem;
Epidemiological data of different human papillomavirus genotypes in cervical specimens of HIV-1-infected women without history of cervical pathology.
Journal of acquired immune deficiency syndromes (1999) 2009;50(2):168-75.
2009: Ballana Ester; Pauls Eduardo; Senserrich Jordi; Clotet Bonaventura; Perron-Sierra Françoise; Tucker Gordon C; Esté José A
Cell adhesion through alphaV-containing integrins is required for efficient HIV-1 infection in macrophages.
Blood 2009;113(6):1278-86.
2009: Pauls Eduardo; Ballana Ester; Moncunill Gemma; Bofill Margarida; Clotet Bonaventura; Ramo-Tello Cristina; Esté José A
Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4.
AIDS (London, England) 2009;23(2):266-8.
2009: Massanella Marta; Puigdomènech Isabel; Cabrera Cecilia; Fernandez-Figueras Maria Teresa; Aucher Anne; Gaibelet Gerald; Hudrisier Denis; García Elisabet; Bofill Margarita; Clotet Bonaventura; Blanco Julià
Antigp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells.
AIDS (London, England) 2009;23(2):183-8.
2009: Dalmau Judith; Puertas Maria Carmen; Azuara Marta; Mariño Ana; Frahm Nicole; Mothe Beatriz; Izquierdo-Useros Nuria; Buzón Maria José; Paredes Roger; Matas Lourdes; Allen Todd M; Brander Christian; Rodrigo Carlos; Clotet Bonaventura; Martinez-Picado Javier
Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;48(2):229-38.
2009: Puigdomènech Isabel; Massanella Marta; Cabrera Cecilia; Clotet Bonaventura; Blanco Julià
On the steps of cell-to-cell HIV transmission between CD4 T cells.
Retrovirology 2009;6():89.
2009: Pulido Federico; Pérez-Valero Ignacio; Delgado Rafael; Arranz Alberto; Pasquau Juan; Portilla Joaquín; Rubio Rafael; González-García Juan; Miralles Pilar; Pérez-Elías Maria J; Ocampo Antonio; Hernando Asunción; Estrada Vicente; Clotet Bonaventura; Podzamczer Daniel; Arribas José R
Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression.
Antiviral therapy 2009;14(2):195-201.
2009: Horne Robert; Kovacs Colin; Katlama Christine; Clotet Bonaventura; Fumaz Carmina R; Youle Michael; Kulasegaram Ranjababu; Fisher Martin; Cohen Calvin; Slim Jihad; Shalit Peter; Cooper Vanessa; Tsoukas Christos
Prescribing and using self-injectable antiretrovirals: how concordant are physician and patient perspectives?
AIDS research and therapy 2009;6():2.
2008: Moltó José; Clotet Bonaventura
[Lopinavir/ritonavir monotherapy as a simplification strategy in antiretroviral therapy in clinical practice]
Enfermedades infecciosas y microbiología clínica 2008;26 Suppl 16():24-6.
2008: Darwich Laila; Cabrera Cecilia; Romeu Joan; Martinez-Picado Javier; Esté José A; Tural Cristina; Bellido Rocio; Clotet Bonaventura; Angulo Ana; Ruiz Lidia; Bofill Margarita
The magnitude of interferon-gamma responses to human cytomegalovirus is predictive for HIV-1 disease progression.
Journal of acquired immune deficiency syndromes (1999) 2008;49(5):507-12.
2008: Tedaldi Ellen; Peters Lars; Neuhaus Jacquie; Puoti Massimo; Rockstroh Jürgen; Klein Marina B; Dore Gregory J; Mocroft Amanda; Soriano Vincent; Clotet Bonaventura; Lundgren Jens D;
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;47(11):1468-75.
2008: Clotet Bonaventura; Capetti Amedeo; Soto-Ramirez Luis E; Gatell Jose M; Rowell Lucy; Salgo Miklos; Schapiro Jonathan M
A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study.
The Journal of antimicrobial chemotherapy 2008;62(6):1374-8.
2008: Moltó José; Santos José R; Pérez-Alvarez Nuria; Cedeño Samandhy; Miranda Cristina; Khoo Saye; Else Laura; Llibre Josep Maria; Valle Marta; Clotet Bonaventura
Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.
Antimicrobial agents and chemotherapy 2008;52(11):3928-32.
2008: Llibre J M; Santos J R; Puig T; Moltó J; Ruiz L; Paredes R; Clotet B
Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.
The Journal of antimicrobial chemotherapy 2008;62(5):909-13.
2008: Bosch Berta; Grigorov Boyan; Senserrich Jordi; Clotet Bonaventura; Darlix Jean-Luc; Muriaux Delphine; Este José A
A clathrin-dynamin-dependent endocytic pathway for the uptake of HIV-1 by direct T cell-T cell transmission.
Antiviral research 2008;80(2):185-93.
2008: Clotet Bonaventura
[Position of darunavir in antiretroviral therapy]
Enfermedades infecciosas y microbiología clínica 2008;26 Suppl 10():61-2.
2008: Moltó José; Valle Marta; Clotet Bonaventura
[Pharmacological interactions with darunavir]
Enfermedades infecciosas y microbiología clínica 2008;26 Suppl 10():43-50.
2008: Clotet Bonaventura
[Introduction. Darunavir.]
Enfermedades infecciosas y microbiología clínica 2008;26 Suppl 10():1-2.
2008: Muñoz-Moreno Jose A; Fumaz Carmina R; Ferrer Maria J; Prats Anna; Negredo Eugènia; Garolera Maite; Pérez-Alvarez Núria; Moltó José; Gómez Guadalupe; Clotet Bonaventura
Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients.
AIDS research and human retroviruses 2008;24(10):1301-7.
2008: Cozzi-Lepri Alessandro; Phillips Andrew N; Clotet Bonaventura; Mocroft Amanda; Ruiz Lidia; Kirk Ole; Lazzarin Adriano; Wiercinska-Drapalo Alicja; Karlsson Anders; Lundgren Jens D;
Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
AIDS (London, England) 2008;22(16):2187-98.
2008: Gulick Roy M; Lalezari Jacob; Goodrich James; Clumeck Nathan; DeJesus Edwin; Horban Andrzej; Nadler Jeffrey; Clotet Bonaventura; Karlsson Anders; Wohlfeiler Michael; Montana John B; McHale Mary; Sullivan John; Ridgway Caroline; Felstead Steve; Dunne Michael W; van der Ryst Elna; Mayer Howard;
Maraviroc for previously treated patients with R5 HIV-1 infection.
The New England journal of medicine 2008;359(14):1429-41.
2008: Elliott Julian H; Lynen Lut; Calmy Alexandra; De Luca Andrea; Shafer Robert W; Zolfo Maria; Clotet Bonaventura; Huffam Sarah; Boucher Charles A B; Cooper David A; Schapiro Jonathan M
Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching.
AIDS (London, England) 2008;22(16):2053-67.
2008: Pettersson Sofia; Pérez-Nueno Violeta I; Ros-Blanco Laia; Puig de La Bellacasa Raimon; Rabal María Obdulia; Batllori Xavier; Clotet Bonaventura; Clotet-Codina Imma; Armand-Ugón Mercedes; Esté José; Borrell José I; Teixidó Jordi
Discovery of novel non-cyclam polynitrogenated CXCR4 coreceptor inhibitors.
ChemMedChem 2008;3(10):1549-57.
2008: Moltó José; Valle Marta; Miranda Cristina; Cedeño Samandhy; Miranda José; Santos José Ramón; Negredo Eugenia; Vilaró Josep; Costa Joan; Clotet Bonaventura
Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.
The Journal of antimicrobial chemotherapy 2008;62(4):784-92.
2008: Hirsch Martin S; Günthard Huldrych F; Schapiro Jonathan M; Brun-Vézinet Françoise; Clotet Bonaventura; Hammer Scott M; Johnson Victoria A; Kuritzkes Daniel R; Mellors John W; Pillay Deenan; Yeni Patrick G; Jacobsen Donna M; Richman Douglas D;
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2008;16(3):266-85.
2008: Llibre J M; Bonjoch A; Iribarren J; Galindo M J; Negredo E; Domingo P; Pérez-Alvarez N; Martinez-Picado J; Schapiro J; Clotet B;
Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
HIV medicine 2008;9(7):508-13.
2008: Cooper David A; Steigbigel Roy T; Gatell Jose M; Rockstroh Jurgen K; Katlama Christine; Yeni Patrick; Lazzarin Adriano; Clotet Bonaventura; Kumar Princy N; Eron Joseph E; Schechter Mauro; Markowitz Martin; Loutfy Mona R; Lennox Jeffrey L; Zhao Jing; Chen Joshua; Ryan Desmond M; Rhodes Rand R; Killar John A; Gilde Lucinda R; Strohmaier Kim M; Meibohm Anne R; Miller Michael D; Hazuda Daria J; Nessly Michael L; DiNubile Mark J; Isaacs Robin D; Teppler Hedy; Nguyen Bach-Yen;
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
The New England journal of medicine 2008;359(4):355-65.
2008: Steigbigel Roy T; Cooper David A; Kumar Princy N; Eron Joseph E; Schechter Mauro; Markowitz Martin; Loutfy Mona R; Lennox Jeffrey L; Gatell Jose M; Rockstroh Jurgen K; Katlama Christine; Yeni Patrick; Lazzarin Adriano; Clotet Bonaventura; Zhao Jing; Chen Joshua; Ryan Desmond M; Rhodes Rand R; Killar John A; Gilde Lucinda R; Strohmaier Kim M; Meibohm Anne R; Miller Michael D; Hazuda Daria J; Nessly Michael L; DiNubile Mark J; Isaacs Robin D; Nguyen Bach-Yen; Teppler Hedy;
Raltegravir with optimized background therapy for resistant HIV-1 infection.
The New England journal of medicine 2008;359(4):339-54.
2008: Autran Brigitte; Murphy Robert L; Costagliola Dominique; Tubiana Roland; Clotet Bonaventura; Gatell Jose; Staszewski Schlomo; Wincker Norma; Assoumou Lambert; El-Habib Raphaelle; Calvez Vincent; Walker Bruce; Katlama Christine;
Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452).
AIDS (London, England) 2008;22(11):1313-22.
2008: Hirsch Martin S; Günthard Huldrych F; Schapiro Jonathan M; Brun-Vézinet Françoise; Clotet Bonaventura; Hammer Scott M; Johnson Victoria A; Kuritzkes Daniel R; Mellors John W; Pillay Deenan; Yeni Patrick G; Jacobsen Donna M; Richman Douglas D
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;47(2):266-85.
2008: Bannister Wendy P; Cozzi-Lepri Alessandro; Clotet Bonaventura; Mocroft Amanda; Kjaer Jesper; Reiss Peter; von Wyl Viktor; Lazzarin Adriano; Katlama Christine; Phillips Andrew N; Ruiz Lidia; Lundgren Jens D;
Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study.
Journal of acquired immune deficiency syndromes (1999) 2008;48(3):324-33.
2008: Darwich Laila; Esteve Anna; Ruiz Lidia; Paredes Roger; Bellido Rocio; Cabrera Cecilia; Romeu Joan; Bofill Margarita; Clotet Bonaventura; Martinez-Picado Javier
Drug-resistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptions.
AIDS research and human retroviruses 2008;24(5):725-32.
2008: Moncunill Gemma; Armand-Ugón Mercedes; Clotet-Codina Imma; Pauls Eduardo; Ballana Ester; Llano Anuska; Romagnoli Barbara; Vrijbloed Jan W; Gombert Frank O; Clotet Bonaventura; De Marco Steve; Esté José A
Anti-HIV activity and resistance profile of the CXC chemokine receptor 4 antagonist POL3026.
Molecular pharmacology 2008;73(4):1264-73.
2008: Johnson Victoria A; Brun-Vezinet Francoise; Clotet Bonaventura; Gunthard Huldrych F; Kuritzkes Daniel R; Pillay Deenan; Schapiro Jonathan M; Richman Douglas D
Update of the Drug Resistance Mutations in HIV-1: Spring 2008.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2008;16(1):62-8.
2008: Angus Brian; Lampe Fiona; Tambussi Guiseppe; Duvivier Claudine; Katlama Christine; Youle Mike; Williams Ian; Clotet Bonaventura; Fisher Martin; Post Frank A; Babiker Abdul; Phillips Andrew;
TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals.
AIDS (London, England) 2008;22(6):737-40.
2008: Senserrich Jordi; Pauls Eduardo; Armand-Ugón Mercedes; Clotet-Codina Imma; Moncunill Gemma; Clotet Bonaventura; Esté Jose A
HIV-1 resistance to the anti-HIV activity of a shRNA targeting a dual-coding region.
Virology 2008;372(2):421-9.
2008: Negredo Eugenia; Puigdomènech Isabel; Marfil Silvia; Puig Jordi; Pérez-Alvarez Núria; Ruiz Lidia; Rey-Joly Celestino; Clotet Bonaventura; Blanco Julià
Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART.
The Journal of antimicrobial chemotherapy 2008;61(2):400-4.
2008: Minuesa Gerard; Purcet Sergi; Erkizia Itziar; Molina-Arcas Míriam; Bofill Margarita; Izquierdo-Useros Nuria; Casado F Javier; Clotet Bonaventura; Pastor-Anglada Marçal; Martinez-Picado Javier
Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells.
The Journal of pharmacology and experimental therapeutics 2008;324(2):558-67.
2008: Franco Sandra; Clotet Bonaventura; Martínez Miguel Angel
A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals.
Virus research 2008;131(2):260-70.
2008: Mocroft A; Horban A; Clotet B; d'Arminio Monforte A; Bogner J R; Aldins P; Staub T; Antunes F; Katlama C; Lundgren J D;
Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999.
HIV medicine 2008;9(1):41-6.
2008: Bannister Wendy P; Ruiz Lidia; Cozzi-Lepri Alessandro; Mocroft Amanda; Kirk Ole; Staszewski Schlomo; Loveday Clive; Karlsson Anders; Monforte Antonella d'Arminio; Clotet Bonaventura; Lundgren Jens D;
Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
AIDS (London, England) 2008;22(3):367-76.
2008: Opravil Milos; Sasadeusz Joe; Cooper David A; Rockstroh Jürgen K; Clumeck Nathan; Clotet Bonaventura; Montaner Julio; Torriani Francesca J; Depamphilis Jean; Dieterich Douglas T
Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection.
Journal of acquired immune deficiency syndromes (1999) 2008;47(1):36-49.
2008: Kuntzen Thomas; Tural Cristina; Li Bin; Feldmann Georg; Kupfer Bernd; Nischalke Hans Dieter; Clotet Bonaventura; Sauerbruch Tilman; Rockstroh Juergen K; Spengler Ulrich
Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART.
AIDS (London, England) 2008;22(2):203-10.
2008: Moncunill Gemma; Armand-Ugón Mercedes; Pauls Eduardo; Clotet Bonaventura; Esté José A
HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro.
AIDS (London, England) 2008;22(1):23-31.
2008: Clotet Bonaventura
Once-daily dosing of nevirapine in HAART.
The Journal of antimicrobial chemotherapy 2008;61(1):13-6.
2008: Llibre Josep M; Domingo Pere; del Pozo Miguel A; Miralles Celia; Galindo Maria J; Viciana Isabel; Moreno Santiago; Schapiro Jonathan M; Clotet Bonaventura
Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients.
The Journal of antimicrobial chemotherapy 2008;61(1):206-9.
2008: Sirera Guillem; Videla Sebastià; López-Blázquez Raquel; Llatjos Mariona; Tarrats Antoni; Castellà Eva; Grane Nuria; Tural Cristina; Rey-Joly Celestino; Clotet Bonaventura
Highly active antiretroviral therapy and incidence of cervical squamous intraepithelial lesions among HIV-infected women with normal cytology and CD4 counts above 350 cells/mm3.
The Journal of antimicrobial chemotherapy 2008;61(1):191-4.
2008: Tural Cristina; Galeras Josep Antón; Planas Ramon; Coll Susanna; Sirera Guillem; Giménez Dolors; Salas Anna; Rey-Joly Celestino; Cirera Isabel; Márquez Carmen; Tor Jordi; Videla Sebastià; García-Retortillo Montserrat; Clotet Bonaventura; Solà Ricard
Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients.
Antiviral therapy 2008;13(8):1047-55.
2008: Darwich Laila; Esteve Anna; Ruiz Lidia; Bellido Rocio; Clotet Bonaventura; Martinez-Picado Javier
Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.
Antiviral therapy 2008;13(7):945-51.
2008: Buzón Maria José; Marfil Silvia; Puertas Maria C; Garcia Elisabet; Clotet Bonaventura; Ruiz Lidia; Blanco Julìa; Martinez-Picado Javier; Cabrera Cecilia
Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.
Antiviral therapy 2008;13(7):881-93.
2008: Sirera Guillem; Videla Sebastià; Romeu Joan; Cañadas Maripaz; Fernández Maria-Teresa; Balo Susana; Cirauqui Beatriz; Darwich Laila; Rey-Joly Celestino; Clotet Bonaventura
Fatal Fast-Evolution of Nasopharyngeal Squamous Cell Carcinoma in an HIV Patient with EBV and HPV (-16 AND -33) in Blood Serum.
The open AIDS journal 2008;2():1-2.
2008: Moltó José; Barbanoj Manuel José; Miranda Cristina; Blanco Asunción; Santos José Ramón; Negredo Eugenia; Costa Joan; Domingo Pere; Clotet Bonaventura; Valle Marta
Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults.
Clinical pharmacokinetics 2008;47(10):681-92.
2008: Deforche Koen; Cozzi-Lepri Alessandro; Theys Kristof; Clotet Bonaventura; Camacho Ricardo J; Kjaer Jesper; Van Laethem Kristel; Phillips Andrew; Moreau Yves; Lundgren Jens D; Vandamme Anne-Mieke;
Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response.
Antiviral therapy 2008;13(3):399-407.
2008: Negredo Eugènia; Garrabou Glòria; Puig Jordi; Lòpez Sònia; Morén Constanza; Bellido Rocio; Ayen Rafaela; Cardellach Francesc; Miró Oscar; Clotet Bonaventura
Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens.
Antiviral therapy 2008;13(2):231-40.
2008: Puigdomènech Isabel; Massanella Marta; Izquierdo-Useros Nuria; Ruiz-Hernandez Raul; Curriu Marta; Bofill Margarita; Martinez-Picado Javier; Juan Manel; Clotet Bonaventura; Blanco Julià
HIV transfer between CD4 T cells does not require LFA-1 binding to ICAM-1 and is governed by the interaction of HIV envelope glycoprotein with CD4.
Retrovirology 2008;5():32.
2007: Muñoz-Moreno Jose A; Fumaz Carmina R; Ferrer Maria J; Tuldrà Albert; Rovira Tatiana; Viladrich Carme; Bayés Ramon; Burger David M; Negredo Eugènia; Clotet Bonaventura;
Assessing self-reported adherence to HIV therapy by questionnaire: the SERAD (Self-Reported Adherence) Study.
AIDS research and human retroviruses 2007;23(10):1166-75.
2007: Ceccherini-Silberstein Francesca; Cozzi-Lepri Alessandro; Ruiz Lidia; Mocroft Amanda; Phillips Andrew N; Olsen Christian Holkmann; Gatell Jose M; Gunthard Huldrych F; Reiss Peter; Perno Carlo Federico; Clotet Bonaventura; Lundgren Jens D;
Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients.
The Journal of infectious diseases 2007;196(8):1180-90.
2007: Moltó José; Santos José Ramón; Valle Marta; Miranda Cristina; Miranda José; Blanco Asunción; Negredo Eugenia; Clotet Bonaventura
Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
Therapeutic drug monitoring 2007;29(5):648-51.
2007: Fox Zoe V; Geretti Anna Maria; Kjaer Jesper; Dragsted Ulrik Bak; Phillips Andrew N; Gerstoft Jan; Staszewski Schlomo; Clotet Bonaventura; von Wyl Viktor; Lundgren Jens D
The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors.
AIDS (London, England) 2007;21(15):2033-42.
2007: Tural C; Solà R; Rubio R; Santín M; Planas R; Quereda C; Berenguer J; Montes-Ramírez M; Clotet B;
Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
Journal of viral hepatitis 2007;14(10):704-13.
2007: Nattermann Jacob; Vogel Martin; Berg Thomas; Danta Mark; Axel Baumgarten; Mayr Christoph; Bruno Raffaele; Tural Christina; Klausen Gerd; Clotet Bonaventura; Lutz Thomas; Grünhage Frank; Rausch Michael; Nischalke Hans Dieter; Schewe Knud; Bienek Bernhard; Haerter Georg; Sauerbruch Tilman; Rockstroh Juergen K; Spengler Ulrich;
Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients.
Hepatology (Baltimore, Md.) 2007;46(4):1016-25.
2007: Gimenez-Barcons Mireia; Clotet Bonaventura; Martinez Miguel Angel
Endoribonuclease-prepared short interfering RNAs induce effective and specific inhibition of human immunodeficiency virus type 1 replication.
Journal of virology 2007;81(19):10680-6.
2007: Wainberg Mark A; Clotet Bonaventura
Review: immunologic response to protease inhibitor-based highly active antiretroviral therapy: a review.
AIDS patient care and STDs 2007;21(9):609-20.
2007: Sirera Guillem; Videla Sebastià; López-Blázquez Raquel; Llatjos Mariona; Tarrats Antoni; Castellà Eva; Grane Nuria; Alcalde Carmen; Tural Cristina; Rey-Joly Celestino; Clotet Bonaventura
Evolution of cervical cytologic changes among HIV-infected women with normal cytology in the HAART era.
AIDS research and human retroviruses 2007;23(8):965-71.
2007: Johnson Victoria A; Brun-Vézinet Françoise; Clotet Bonaventura; Günthard Huldrych F; Kuritzkes Daniel R; Pillay Deenan; Schapiro Jonathan M; Richman Douglas D
Update of the drug resistance mutations in HIV-1: 2007.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2007;15(4):119-25.
2007: Reynes Jacques; Arastéh Keikawus; Clotet Bonaventura; Cohen Calvin; Cooper David A; Delfraissy Jean-François; Eron Joseph J; Henry Keith; Katlama Christine; Kuritzkes Daniel R; Lalezari Jacob P; Lange Joep; Lazzarin Adriano; Montaner Julio S G; Nelson Mark; O' Hearn Mary; Stellbrink Hans-Jürgen; Trottier Benoit; Walmsley Sharon L; Buss Neil E; Demasi Ralph; Chung Jain; Donatacci Lucille; Guimaraes Denise; Rowell Lucy; Valentine Adeline; Wilkinson Martin; Salgo Miklos P
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
AIDS patient care and STDs 2007;21(8):533-43.
2007: Clotet Bonaventura; Negredo Eugenia; Girard Pierre Marie; Youle Mike; Neubacher Dietmar
Compromised immunologic recovery in patients receiving tipranavir/ritonavir coadministered with tenofovir and didanosine in Randomized Evaluation of Strategic Intervention in multidrug-resiStant patients with tipranavir (RESIST) studies.
Journal of acquired immune deficiency syndromes (1999) 2007;45(4):479-81.
2007: Moltó José; Santos José Ramón; Negredo Eugenia; Miranda Cristina; Videla Sebastià; Clotet Bonaventura
Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice.
The Journal of antimicrobial chemotherapy 2007;60(2):436-9.
2007: Rachlis Anita; Clotet Bonaventura; Baxter John; Murphy Robert; Lefebvre Eric
Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3.
HIV clinical trials 2007;8(4):213-20.
2007: Lazzarin Adriano; Campbell Thomas; Clotet Bonaventura; Johnson Margaret; Katlama Christine; Moll Arend; Towner William; Trottier Benoit; Peeters Monika; Vingerhoets Johan; de Smedt Goedele; Baeten Benny; Beets Greet; Sinha Rekha; Woodfall Brian;
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.
Lancet 2007;370(9581):39-48.
2007: Clotet Bonaventura
CCR5 inhibitors: promising yet challenging.
The Journal of infectious diseases 2007;196(2):178-80.
2007: Izquierdo-Useros Nuria; Blanco Julià; Erkizia Itziar; Fernández-Figueras Maria Teresa; Borràs Francesc E; Naranjo-Gómez Mar; Bofill Margarita; Ruiz Lidia; Clotet Bonaventura; Martinez-Picado Javier
Maturation of blood-derived dendritic cells enhances human immunodeficiency virus type 1 capture and transmission.
Journal of virology 2007;81(14):7559-70.
2007: de Arquer Guillermo Robert; Peña Ruth; Cabrera Cecilia; Coma Gemma; Ruiz-Hernandez Raul; Guerola Rosa; Clotet Bonaventuta; Ruiz Lidia; Esté José A; Calle M Luz; Bofill Margarita
Skewed expression and up-regulation of the IL-12 and IL-18 receptors in resting and activated CD4 T cells from HIV-1-infected patients.
Journal of leukocyte biology 2007;82(1):72-8.
2007: Nelson Mark R; Katlama Christine; Montaner Julio S; Cooper David A; Gazzard Brian; Clotet Bonaventura; Lazzarin Adriano; Schewe Knud; Lange Joep; Wyatt Christina; Curtis Sue; Chen Shan-Shan; Smith Stephen; Bischofberger Norbert; Rooney James F
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.
AIDS (London, England) 2007;21(10):1273-81.
2007: Moltó José; Blanco Asunción; Miranda Cristina; Miranda José; Puig Jordi; Valle Marta; Delavarga Meritxell; Fumaz Carmina R; Barbanoj Manuel José; Clotet Bonaventura
Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice.
British journal of clinical pharmacology 2007;63(6):715-21.
2007: Villena Cristina; Prado Julia G; Puertas Maria Carmen; Martínez Miguel Angel; Clotet Bonaventura; Ruiz Lidia; Parkin Neil T; Menéndez-Arias Luis; Martinez-Picado Javier
Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region.
Journal of virology 2007;81(9):4713-21.
2007: Clotet Bonaventura; Bellos Nicholas; Molina Jean-Michel; Cooper David; Goffard Jean-Christophe; Lazzarin Adriano; Wöhrmann Andrej; Katlama Christine; Wilkin Timothy; Haubrich Richard; Cohen Calvin; Farthing Charles; Jayaweera Dushyantha; Markowitz Martin; Ruane Peter; Spinosa-Guzman Sabrina; Lefebvre Eric;
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
Lancet 2007;369(9568):1169-78.
2007: Franco Sandra; Parera Mariona; Aparicio Ester; Clotet Bonaventura; Martinez Miguel Angel
Genetic and catalytic efficiency structure of an HCV protease quasispecies.
Hepatology (Baltimore, Md.) 2007;45(4):899-910.
2007: Clotet Bonaventura; Paredes Roger
Clinical approach to drug resistance interpretation: expert advice.
Current opinion in HIV and AIDS 2007;2(2):145-9.
2007: Cozzi-Lepri Alessandro; Phillips Andrew N; Ruiz Lidia; Clotet Bonaventura; Loveday Clive; Kjaer Jesper; Mens Helene; Clumeck Nathan; Viksna Ludmila; Antunes Francisco; Machala Ladislav; Lundgren Jens D;
Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.
AIDS (London, England) 2007;21(6):721-32.
2007: Negredo Eugènia; Martínez Eva; Cinquegrana Denise; Estany Carla; Clotet Bonaventura
Therapeutic management of bone demineralization in the HIV-infected population.
AIDS (London, England) 2007;21(6):657-63.
2007: Fernàndez Guerau; Clotet Bonaventura; Martínez Miguel Angel
Fitness landscape of human immunodeficiency virus type 1 protease quasispecies.
Journal of virology 2007;81(5):2485-96.
2007: Parera Mariona; Fernàndez Guerau; Clotet Bonaventura; Martínez Miguel Angel
HIV-1 protease catalytic efficiency effects caused by random single amino acid substitutions.
Molecular biology and evolution 2007;24(2):382-7.
2007: Franco Sandra; Tural Cristina; Clotet Bonaventura; Martínez Miguel Angel
Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1.
Virus research 2007;123(2):161-9.
2007: Ruiz Lidia; Paredes Roger; Gómez Guadalupe; Romeu Joan; Domingo Pere; Pérez-Alvarez Nuria; Tambussi Giuseppe; Llibre Josep Maria; Martínez-Picado Javier; Vidal Francesc; Fumaz Carmina R; Clotet Bonaventura;
Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
AIDS (London, England) 2007;21(2):169-78.
2007: Pauls E; Senserrich J; Bofill M; Clotet B; Esté J A
Induction of interleukins IL-6 and IL-8 by siRNA.
Clinical and experimental immunology 2007;147(1):189-96.
2007: Fumaz C R; Muñoz-Moreno J A; Ballesteros A L; Paredes R; Ferrer M J; Salas A; Fuster D; Masmitjà E; Pérez-Alvarez N; Gómez G; Tural C; Clotet B
Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients.
AIDS care 2007;19(1):138-45.
2007: Moltó José; Valle Marta; Blanco Asunción; Negredo Eugenia; DelaVarga Meritxell; Miranda Cristina; Miranda José; Domingo Pere; Vilaró Josep; Tural Cristina; Costa Joan; Barbanoj Manuel José; Clotet Bonaventura
Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis.
Clinical pharmacokinetics 2007;46(1):85-92.
2006: Negredo Eugenia; Higueras Carmen; Adell Xavier; Martinez Juan Carlos; Martinez Eva; Puig Jordi; Fumaz Carmina R; Muñoz-Moreno Jose A; Perez-Alvarez Nuria; Videla Sebastia; Estany Carla; Cinquegrana Denise; Gonzalez-Mestre Vicente; Clotet Bonaventura
Reconstructive treatment for antiretroviral-associated facial lipoatrophy: a prospective study comparing autologous fat and synthetic substances.
AIDS patient care and STDs 2006;20(12):829-37.
2006: Negredo Eugenia; Moltó José; Puig Jordi; Cinquegrana Denise; Bonjoch Anna; Pérez-Alvarez Núria; López-Blázquez Raquel; Blanco Asunción; Clotet Bonaventura; Rey-Joly Celestino
Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins.
AIDS (London, England) 2006;20(17):2159-64.
2006: Moltó José; Blanco Asunción; Miranda Cristina; Miranda José; Puig Jordi; Valle Marta; DelaVarga Meritxell; Fumaz Carmina R; Barbanoj Manuel José; Clotet Bonaventura
Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice.
British journal of clinical pharmacology 2006;62(5):560-6.
2006: Cabrera Cecilia; Marfil Silvia; García Elisabet; Martinez-Picado Javier; Bonjoch Anna; Bofill Margarita; Moreno Santiago; Ribera Esteban; Domingo Pere; Clotet Bonaventura; Ruiz Lidia
Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen.
AIDS (London, England) 2006;20(16):2075-80.
2006: Bofill Margarita; Martinez-Picado Javier; Ruiz-Hernandez Raul; Cabrera Cecilia; Marfil Silvia; Erkizia Itziar; Bellido Rocio; Romeu Joan; Clotet Bonaventura; Ruiz Lidia
Naive CD4(+) T cells and recent thymic emigrant levels in treated individuals with HIV: clinical relevance.
AIDS research and human retroviruses 2006;22(9):893-6.
2006: Bonjoch Anna; Negredo Eugenia; Puig Jordi; Erkizia Itziar; Puig Teresa; Cabrera Cecilia; Ruiz Lidia; Clotet Bonaventura
Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide.
AIDS (London, England) 2006;20(14):1896-8.
2006: Coma G; Peña R; Blanco J; Rosell A; Borras F E; Esté J A; Clotet B; Ruiz L; Parkhouse R M E; Bofill M
Treatment of monocytes with interleukin (IL)-12 plus IL-18 stimulates survival, differentiation and the production of CXC chemokine ligands (CXCL)8, CXCL9 and CXCL10.
Clinical and experimental immunology 2006;145(3):535-44.
2006: Pauls Eduardo; Senserrich Jordi; Clotet Bonaventura; Esté Jose A
Inhibition of HIV-1 replication by RNA interference of p53 expression.
Journal of leukocyte biology 2006;80(3):659-67.
2006: Johnson Victoria A; Brun-Vezinet Francoise; Clotet Bonaventura; Kuritzkes Daniel R; Pillay Deenan; Schapiro Jonathan M; Richman Douglas D
Update of the drug resistance mutations in HIV-1: Fall 2006.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2006;14(3):125-30.
2006: Hicks Charles B; Cahn Pedro; Cooper David A; Walmsley Sharon L; Katlama Christine; Clotet Bonaventura; Lazzarin Adriano; Johnson Margaret A; Neubacher Dietmar; Mayers Douglas; Valdez Hernan;
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
Lancet 2006;368(9534):466-75.
2006: Negredo Eugènia; Bonjoch Anna; Clotet Bonaventura
Benefits and concerns of simplification strategies in HIV-infected patients.
The Journal of antimicrobial chemotherapy 2006;58(2):235-42.
2006: López Juan Carlos; Moreno Santiago; Jiménez-Oñate Fernando; Clotet Bonaventura; Rubio Rafael; Hernández-Quero Jose
A cohort study of the food effect on virological failure and treatment discontinuation in patients on HAART containing didanosine enteric-coated capsules (FOODDIe Study).
HIV clinical trials 2006;7(4):155-62.
2006: Gumá Monica; Cabrera Cecilia; Erkizia Itziar; Bofill Margarita; Clotet Bonaventura; Ruiz Lidia; López-Botet Miguel
Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients.
The Journal of infectious diseases 2006;194(1):38-41.
2006: Solà Ricard; Galeras Josep Antón; Montoliu Silvia; Tural Cristina; Force Lluis; Torra Sandra; Montull Santiago; Castro Eduardo Rodríguez De; Coll Susanna; Fuster Daniel; Barrufet Pilar; Sirera Guillem; Giménez Maria Dolors; Clotet Bonaventura; Planas Ramón
Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment.
AIDS research and human retroviruses 2006;22(5):393-400.
2006: Sirera Guillem; Videla Sebastià; Piñol Marta; Cañadas Mari P; Llatjos Mariona; Ballesteros Angel L; García-Cuyás Francisco; Castellá Eva; Guerola Rosa; Tural Cristina; Rey-Joly Celestino; Clotet Bonaventura
High prevalence of human papillomavirus infection in the anus, penis and mouth in HIV-positive men.
AIDS (London, England) 2006;20(8):1201-4.
2006: Fernàndez Guerau; Llano Anuska; Esgleas Miriam; Clotet Bonaventura; Esté José A; Martínez Miguel Angel
Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses.
The Journal of general virology 2006;87(Pt 5):1285-94.
2006: Cabrera Cecilia; Clotet Bonaventura
[Resistance genotyping in patients with therapeutic failure]
Enfermedades infecciosas y microbiología clínica 2006;24(4):219-21.
2006: Bonjoch Anna; Paredes Roger; Domingo Pere; Cervantes Manel; Pedrol Enric; Ribera Esteve; Force Lluís; Llibre Josep M; Vilaró Josep; Dalmau David; Cucurull Josep; Mascaró Jaume; Masabeu Angels; Pérez-Alvarez Núria; Puig Jordi; Cinquegrana Denise; Clotet Bonaventura
Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients.
AIDS research and human retroviruses 2006;22(4):321-9.
2006: Youle Mike; Staszweski Schlomo; Clotet Bonaventura; Arribas José Ramon; Blaxhult Anders; Carosi Giampiero; Dejesus Edwin; Di Perri Gianni; Estrada Vicente; Fisher Martin; Kovacs Colin; Kulasegaram Ranjababu; Lazzarin Adriano; Marriott Debbie; Muñoz Leopoldo; Reynes Jacques; Shalit Peter; Slim Jihad; Tsoukas Chris; Vaccaro Anthony; Vera José
Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations.
HIV clinical trials 2006;7(2):86-96.
2006: Draenert Rika; Allen Todd M; Liu Yang; Wrin Terri; Chappey Colombe; Verrill Cori L; Sirera Guillem; Eldridge Robert L; Lahaie Matthew P; Ruiz Lidia; Clotet Bonaventura; Petropoulos Christos J; Walker Bruce D; Martinez-Picado Javier
Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus.
The Journal of experimental medicine 2006;203(3):529-39.
2006: Bosch Berta; Clotet-Codina Imma; Blanco Julià; Pauls Eduardo; Coma Gemma; Cedeño Samandhy; Mitjans Francesc; Llano Anuska; Bofill Margarita; Clotet Bonaventura; Piulats Jaume; Esté José A
Inhibition of human immunodeficiency virus type 1 infection in macrophages by an alpha-v integrin blocking antibody.
Antiviral research 2006;69(3):173-80.
2006: Negredo Eugènia; Clotet Bonaventura; Puig Jordi; Pérez-Alvarez Núria; Ruiz Lidia; Romeu Joan; Moltó José; Rey-Joly Celestino; Blanco Julià
The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy.
AIDS (London, England) 2006;20(4):619-21.
2006: López Sònia; Negredo Eugènia; Garrabou Glòria; Puig Jordi; Ruiz Lidia; Sanjurjo Eduard; Ramos Xavier; Infante Ana B; Casademont Jordi; Cardellach Francesc; Clotet Bonaventura; Miró Oscar
Longitudinal study on mitochondrial effects of didanosine-tenofovir combination.
AIDS research and human retroviruses 2006;22(1):33-9.
2006: Sabariegos Rosario; Giménez-Barcons Mireia; Tàpia Natalia; Clotet Bonaventura; Martínez Miguel Angel
Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs.
Journal of virology 2006;80(2):571-7.
2006: Purcet Sergi; Minuesa Gerard; Molina-Arcas Míriam; Erkizia Itziar; Casado F Javier; Clotet Bonaventura; Martinez-Picado Javier; Pastor-Anglada Marçal
3'-Azido-2',3'-dideoxythymidine (zidovudine) uptake mechanisms in T lymphocytes.
Antiviral therapy 2006;11(6):803-11.
2006: Fuster Daniel; Planas Ramon; Gonzalez Juan; Force Luís; Cervantes Manel; Vilaró Josep; Roget Mercè; García Isabel; Pedrol Enric; Tor Jordi; Ballesteros Angel L; Salas Anna; Sirera Guillem; Videla Sebastià; Clotet Bonaventura; Tural Cristina
Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response.
Antiviral therapy 2006;11(4):473-82.
2006: Moltó José; Ruiz Lidia; Valle Marta; Martinez-Picado Javier; Bonjoch Ana; Bravo Isabel; Negredo Eugenia; Heilek-Sneider Gabrielle M; Clotet Bonaventura
Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
Antiviral therapy 2006;11(1):47-51.
2005: Mocroft Amanda; Soriano Vincent; Rockstroh Jurgen; Reiss Peter; Kirk Ole; de Wit Stephane; Gatell Jose; Clotet Bonaventura; Phillips Andrew N; Lundgren Jens D;
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?
AIDS (London, England) 2005;19(18):2117-25.
2005: Nelson Mark; Arastéh Keikawus; Clotet Bonaventura; Cooper David A; Henry Keith; Katlama Christine; Lalezari Jacob P; Lazzarin Adriano; Montaner Julio S G; O'Hearn Mary; Piliero Peter J; Reynes Jacques; Trottier Benoit; Walmsley Sharon L; Cohen Calvin; Eron Joseph J; Kuritzkes Daniel R; Lange Joep; Stellbrink Hans-Jürgen; Delfraissy Jean-François; Buss Neil E; Donatacci Lucille; Wat Cynthia; Smiley Lynn; Wilkinson Martin; Valentine Adeline; Guimaraes Denise; Demasi Ralph; Chung Jain; Salgo Miklos P
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
Journal of acquired immune deficiency syndromes (1999) 2005;40(4):404-12.
2005: Armand-Ugón Mercedes; Clotet-Codina Imma; Tintori Cristina; Manetti Fabrizio; Clotet Bonaventura; Botta Maurizio; Esté José A
The anti-HIV activity of ADS-J1 targets the HIV-1 gp120.
Virology 2005;343(1):141-9.
2005: Johnson Victoria A; Brun-Vezinet Francoise; Clotet Bonaventura; Conway Brian; Kuritzkes Daniel R; Pillay Deenan; Schapiro Jonathan M; Telenti Amalio; Richman Douglas D
Update of the drug resistance mutations in HIV-1: Fall 2005.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2005;13(4):125-31.
2005: Bosch Berta; Blanco Julià; Pauls Eduardo; Clotet-Codina Imma; Armand-Ugón Mercedes; Grigorov Boyan; Muriaux Delphine; Clotet Bonaventura; Darlix Jean-Luc; Esté José A
Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.
Antimicrobial agents and chemotherapy 2005;49(10):4296-304.
2005: Moncunill Gemma; Negredo Eugenia; Bosch Lluís; Vilarrasa Jaume; Witvrouw Myriam; Llano Anuska; Clotet Bonaventura; Esté José A
Evaluation of the anti-HIV activity of statins.
AIDS (London, England) 2005;19(15):1697-700.
2005: Blanco Julià; Clotet-Codina Imma; Bosch Berta; Armand-Ugón Mercedes; Clotet Bonaventura; Esté José A
Multiparametric assay to screen and dissect the mode of action of anti-human immunodeficiency virus envelope drugs.
Antimicrobial agents and chemotherapy 2005;49(9):3926-9.
2005: Negredo Eugènia; Bonjoch Anna; Paredes Roger; Puig Jordi; Clotet Bonaventura
Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;41(6):901-5.
2005: Prado Julia G; Parkin Neil T; Clotet Bonaventura; Ruiz Lidia; Martinez-Picado Javier
HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;41(5):729-37.
2005: Fuster Daniel; Clotet Bonaventura
Review of atazanavir: a novel HIV protease inhibitor.
Expert opinion on pharmacotherapy 2005;6(9):1565-72.
2005: Bonjoch Anna; Paredes Roger; Galvez Juan; Miralles Celia; Videla Sebastia; Martínez Eva; Miranda Jose; Muñoz-Moreno Jose Antonio; De la Torre Javier; Prieto Arturo; Vilades Consuelo; Clotet Bonaventura;
Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART.
Journal of acquired immune deficiency syndromes (1999) 2005;39(3):313-6.
2005: Tapia Natalia; Fernàndez Guerau; Parera Mariona; Gómez-Mariano Gemma; Clotet Bonaventura; Quiñones-Mateu Miguel; Domingo Esteban; Martínez Miguel Angel
Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection.
Virology 2005;338(1):1-8.
2005: Sirera Guillem; Videla Sebastián; Castellá Eva; Cavallé Lluís; Grané Núria; Llatjos Mariona; Tural Cristina; Negredo Eugenia; Fernández Angela; Rey-Joly Celestino; Clotet Bonaventura
[Contribution of human papillomavirus second-generation hybrid capture test for the diagnosis of cervical pathology in HIV-infected outpatients]
Medicina clínica 2005;125(4):127-31.
2005: Ballesteros Angel Luis; Fuster Daniel; Planas Ramon; Clotet Bonaventura; Tural Cristina
Role of viral kinetics under HCV therapy in HIV/HCV-coinfected patients.
The Journal of antimicrobial chemotherapy 2005;55(6):824-7.
2005: Martinez-Picado Javier; Wrin Terri; Frost Simon D W; Clotet Bonaventura; Ruiz Lidia; Brown Andrew J Leigh; Petropoulos Christos J; Parkin Neil T
Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.
Journal of virology 2005;79(10):5907-13.
2005: Pruvost Alain; Negredo Eugènia; Benech Henri; Theodoro Frédéric; Puig Jordi; Grau Eulàlia; García Elisabet; Moltó José; Grassi Jacques; Clotet Bonaventura
Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients.
Antimicrobial agents and chemotherapy 2005;49(5):1907-14.
2005: Giménez-Barcons Mireia; Ribera Meritxell; Llano Anuska; Clotet Bonaventura; Esté Jose A; Martínez Miguel A
Analysis of chemokine and cytokine expression in patients with HIV and GB virus type C coinfection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;40(9):1342-9.
2005: Cabrera Cecilia; Clotet Bonaventura
[Mutations resulting in resistence of antiretroviral drugs in HIV-infected patients]
Medicina clínica 2005;124(16):618-9.
2005: Jaén Angeles; Casabona Jordi; Esteve Anna; Miró Jose M; Tural Cristina; Ferrer Elena; Riera Melchor; Segura Ferran; Force Lluís; Sued Omar; Vilaró Josep; Masabeu Angels; García Isabel; Dorca Esther; Altès Jordi; Navarro Gemma; Podzamczer Daniel; Villalonga Concepción; Clotet Bonaventura; Gatell Josep M;
[Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project]
Medicina clínica 2005;124(14):525-31.
2005: Fumaz Carmina R; Muñoz-Moreno Jose A; Moltó José; Negredo Eugènia; Ferrer Maria José; Sirera Guillem; Pérez-Alvarez Núria; Gómez Guadalupe; Burger David; Clotet Bonaventura
Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence.
Journal of acquired immune deficiency syndromes (1999) 2005;38(5):560-5.
2005: Johnson Victoria A; Brun-Vezinet Francoise; Clotet Bonaventura; Conway Brian; Kuritzkes Daniel R; Pillay Deenan; Schapiro Jonathan; Telenti Amalio; Richman Douglas
Update of the Drug Resistance Mutations in HIV-1: 2005.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2005;13(1):51-7.
2005: Johnson M; Nieto-Cisneros L; Horban A; Arasteh K; Gonzalez-Garcia J; Artigas J G; Clotet B; Danise A; Landman R; Proll S; Snowden W; Foreman R; Smith P
Comparison of gastrointestinal tolerability and patient preference for treatment with the 625 mg and 250 mg nelfinavir tablet formulations.
HIV medicine 2005;6(2):107-13.
2005: Barrios Ana; Rendón Ana; Negredo Eugenia; Barreiro Pablo; Garcia-Benayas Teresa; Labarga Pablo; Santos Jesús; Domingo Pere; Sánchez-Conde Matilde; Maida Ivana; Martín-Carbonero Luz; Núñez Marina; Blanco Francisco; Clotet Bonaventura; Sambeat Maria Antonia; Gil Paloma; Gonzalez-Lahoz Juan; Cooper David; Soriano Vincent
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.
AIDS (London, England) 2005;19(6):569-75.
2005: Negredo Eugenia; Martínez-López Eva; Paredes Roger; Rosales Joaquim; Pérez-Alvarez Núria; Holgado Susana; Gel Silvia; del Rio Luís; Tena Xavier; Rey-Joly Celestino; Clotet Bonaventura
Reversal of HIV-1-associated osteoporosis with once-weekly alendronate.
AIDS (London, England) 2005;19(3):343-5.
2005: Martinez-Picado Javier; Morales-Lopetegi Kristina; Villena Cristina; Gutiérrez Carolina; Izquierdo Nuria; Marfil Silvia; Clotet Bonaventura; Ruiz Lidia
Evidence for preferential genotyping of a minority human immunodeficiency virus population due to primer-template mismatching during PCR-based amplification.
Journal of clinical microbiology 2005;43(1):436-8.
2005: Negredo Eugènia; Moltó José; Burger David; Côté Helene; Miró Oscar; Ribalta Josep; Martínez Eva; Puig Jordi; Ruiz Lidia; Salazar Juliana; López Sònia; Montaner Julio; Rey-Joly Celestino; Clotet Bonaventura
Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study).
Journal of acquired immune deficiency syndromes (1999) 2005;38(1):47-52.
2005: Fuster Daniel; Huertas Jaime A; Gómez Guadalupe; Solà Ricard; González García Juan; Vilaró Josep; Pedrol Enric; Force Lluís; Tor Jordi; Sirera Guillem; Videla Sebastiá; Planas Ramon; Clotet Bonaventura; Tural Cristina;
Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy.
Antiviral therapy 2005;10(7):841-7.
2005: Barrios Ana; Negredo Eugenia; Domingo Pere; Estrada Vicente; Labarga Pablo; Asensi Víctor; Morales Dolores; Santos Jesús; Clotet Bonaventura; Soriano Vincent;
Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
Antiviral therapy 2005;10(7):825-32.
2005: Cozzi-Lepri Alessandro; Ruiz Lidia; Loveday Clive; Phillips Andrew N; Clotet Bonaventura; Reiss Peter; Ledergerber Bruno; Holkmann Christian; Staszewski Schlomo; Lundgren Jens D;
Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy.
Antiviral therapy 2005;10(7):791-802.
2004: Ballesteros Angel Luis; Miró Oscar; López Sònia; Fuster Daniel; Videla Sebastiá; Martínez Eva; Garrabou Glòria; Salas Anna; Côté Hélène; Tor Jordi; Rey-Joly Celestino; Planas Ramon; Clotet Bonaventura; Tural Cristina
Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both.
Antiviral therapy 2004;9(6):969-77.
2004: Negredo Eugenia; Paredes Roger; Peraire Joaquim; Pedrol Enric; Côté Helene; Gel Silvia; Fumoz Carmina R; Ruiz Lidia; Abril Vicente; Rodriguez de Castro Eduardo; Ochoa Claudia; Martinez-Picado Javier; Montaner Julio; Rey-Joly Celestino; Clotet Bonaventura;
Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study.
Antiviral therapy 2004;9(6):889-93.
2004: Fuster Daniel; Planas Ramon; Muga Robert; Ballesteros Angel L; Santos Justiniano; Tor Jordi; Sirera Guillem; Guardiola Helena; Salas Anna; Cabré Eduard; Ojanguren Isabel; Barluenga Eva; Rey-Joly Celestino; Clotet Bonaventura; Tural Cristina
Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy.
AIDS research and human retroviruses 2004;20(12):1293-7.
2004: Moltó José; Ruiz Lidia; Romeu Joan; Martínez-Picado Javier; Negredo Eugenia; Tural Cristina; Sirera Guillem; Clotet Bonaventura
Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects.
AIDS research and human retroviruses 2004;20(12):1283-8.
2004: Iribarren José Antonio; Labarga Pablo; Rubio Rafael; Berenguer Juan; Miró José M; Antela Antonio; González Juan; Moreno Santiago; Arrizabalaga Julio; Chamorro Lourdes; Clotet Bonaventura; Gatell José M; López-Aldeguer José; Martínez Esteban; Polo Rosa; Tuset Montserrat; Viciana Pompeyo; Santamaría Juan Miguel; Kindelán José María; Ribera Esteve; Segura Ferrán;
[Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)]
Enfermedades infecciosas y microbiología clínica 2004;22(10):564-642.
2004: Parera Mariona; Clotet Bonaventura; Martinez Miguel Angel
Genetic screen for monitoring severe acute respiratory syndrome coronavirus 3C-like protease.
Journal of virology 2004;78(24):14057-61.
2004: Bofill M; Almirall E; McQuaid A; Peña R; Ruiz-Hernandez R; Naranjo M; Ruiz L; Clotet B; Borràs F E
Differential expression of the cytokine receptors for human interleukin (IL)-12 and IL-18 on lymphocytes of both CD45RA and CD45RO phenotype from tonsils, cord and adult peripheral blood.
Clinical and experimental immunology 2004;138(3):460-5.
2004: Blanco Julià; Bosch Berta; Fernández-Figueras María Teresa; Barretina Jordi; Clotet Bonaventura; Esté José A
High level of coreceptor-independent HIV transfer induced by contacts between primary CD4 T cells.
The Journal of biological chemistry 2004;279(49):51305-14.
2004: Moltó José; Clotet Bonaventura
Therapeutic drug monitoring of antiretroviral agents scenario.
Journal of HIV therapy 2004;9(4):75-8.
2004: Ribera Esteban; Lopez Rosa M; Diaz Marjorie; Pou Leonor; Ruiz Lidia; Falcó Vicenç; Crespo Manuel; Azuaje Carlos; Ruiz Isabel; Ocaña Imma; Clotet Bonaventura; Pahissa Albert
Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
Antimicrobial agents and chemotherapy 2004;48(11):4256-62.
2004: Cabrera Cecilia; Cozzi-Lepri Alessandro; Phillips Andrew N; Loveday Clive; Kirk Ole; Ait-Khaled Mounir; Reiss Peter; Kjaer Jesper; Ledergerber Bruno; Lundgren Jens D; Clotet Bonaventura; Ruiz Lidia;
Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
Antiviral therapy 2004;9(5):787-800.
2004: Johnson Victoria A; Brun-Vézinet Francoise; Clotet Bonaventura; Conway Brian; D'Aquila Richard T; Demeter Lisa M; Kuritzkes Daniel R; Pillay Deenan; Schapiro Jonathan M; Telenti Amalio; Richman Douglas D
Update of the drug resistance mutations in HIV-1: 2004.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2004;12(4):119-24.
2004: Tural Cristina; Clotet Bonaventura
[The era of antiretroviral therapy... and the era of hepatitis C virus coinfection]
Medicina clínica 2004;123(12):460-2.
2004: Blanco Julià; Barretina Jordi; Clotet Bonaventura; Esté José A
R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism.
Journal of leukocyte biology 2004;76(4):804-11.
2004: Brun-Vézinet Françoise; Costagliola Dominique; Khaled Mounir Ait; Calvez Vincent; Clavel François; Clotet Bonaventura; Haubrich Richard; Kempf Dale; King Marty; Kuritzkes Daniel; Lanier Randall; Miller Michael; Miller Veronica; Phillips Andrews; Pillay Deenan; Schapiro Jonathan; Scott Janna; Shafer Robert; Zazzi Maurizio; Zolopa Andrew; DeGruttola Victor
Clinically validated genotype analysis: guiding principles and statistical concerns.
Antiviral therapy 2004;9(4):465-78.
2004: Fernandez-Cruz E; Moreno S; Navarro J; Clotet B; Bouza E; Carbone J; Peña J M; Pérez Molina J; Podzamczer D; Rubio R; Ocaña I; Pulido F; Viciana P; Maradona J A; Blazquez R; Barros C; Quereda C; Rodriguez-Sainz C; Gil J; Abad M L; Díaz L; Cantó C; Muñoz M A; Ferrer E; Jou A; Sirera G; Díaz M; Lopez F; Gatell J M; Gonzalez-Lahoz J;
Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects.
Vaccine 2004;22(23-24):2966-73.
2004: Barretina Jordi; Blanco Julià; Bonjoch Anna; Llano Anuska; Clotet Bonaventura; Esté José A
Immunological and virological study of enfuvirtide-treated HIV-positive patients.
AIDS (London, England) 2004;18(12):1673-82.
2004: Prado Julia G; Franco Sandra; Matamoros Tania; Ruiz Lidia; Clotet Bonaventura; Menéndez-Arias Luis; Martínez Miguel Angel; Martinez-Picado Javier
Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215.
Virology 2004;326(1):103-12.
2004: Clotet Bonaventura
Strategies for overcoming resistance in HIV-1 infected patients receiving HAART.
AIDS reviews 2004;6(3):123-30.
2004: Negredo Eugènia; Moltó José; Muñoz-Moreno José Antonio; Pedrol Enric; Ribera Esteve; Viciana Pompeyo; Galindos M José; Miralles Celia; Burger David; Rodriguez Fumaz Carmina; Puig Jordi; Gel Sílvia; Rodríguez Eva; Videla Sebastià; Ruiz Lidia; Clotet Bonaventura
Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.
Antiviral therapy 2004;9(3):335-42.
2004: Paredes Roger; Clotet Bonaventura
[Duration of antiretroviral combinations]
Medicina clínica 2004;122(18):696-7.
2004: Clotet Bonaventura; Raffi François; Cooper David; Delfraissy Jean-François; Lazzarin Adriano; Moyle Graeme; Rockstroh Jürgen; Soriano Vincent; Schapiro Jonathan
Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations.
AIDS (London, England) 2004;18(8):1137-46.
2004: Parera Mariona; Ibañez Angela; Clotet Bonaventura; Martinez Miguel Angel
Lack of evidence for protease evolution in HIV-1-infected patients after 2 years of successful highly active antiretroviral therapy.
The Journal of infectious diseases 2004;189(8):1444-51.
2004: Prado Julia G; Shintani Ayumi; Bofill Margarita; Clotet Bonaventura; Ruiz Lidia; Martinez-Picado Javier
Lack of longitudinal intrapatient correlation between p24 antigenemia and levels of human immunodeficiency virus (HIV) type 1 RNA in patients with chronic hiv infection during structured treatment interruptions.
Journal of clinical microbiology 2004;42(4):1620-5.
2004: Negredo Eugenia; Ribalta Josep; Ferré Raimon; Salazar Juliana; Rey-Joly Celestino; Sirera Guillem; Masana Lluís; Clotet Bonaventura
Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients.
AIDS (London, England) 2004;18(5):819-21.
2004: Clotet Bonaventura
Comparison of regimens as initial therapy for HIV.
The New England journal of medicine 2004;350(10):1053-4; author reply 1053-4.
2004: Negredo Eugenia; Moltó José; Burger David; Viciana Pompeyo; Ribera Esteve; Paredes Roger; Juan Manel; Ruiz Lidia; Puig Jordi; Pruvost Alain; Grassi Jacques; Masmitjà Elisabeth; Clotet Bonaventura
Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.
AIDS (London, England) 2004;18(3):459-63.
2004: Ballesteros Angel Luis; Franco Sandra; Fuster Daniel; Planas Ramón; Martínez Miguel Angel; Acosta Lesly; Sirera Guillem; Salas Anna; Tor Jordi; Rey-Joly Celestino; Clotet Bonaventura; Tural Cristina
Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches.
AIDS (London, England) 2004;18(1):59-66.
2004: Clotet Bonaventura; Carmena Jorge; Pulido Federico; Luque Isabel; Rodriguez-Alcántara Felipe;
Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients.
HIV clinical trials 2004;5(1):33-9.
2003: Walmsley Sharon; Henry Keith; Katlama Christine; Nelson Mark; Castagna Antonella; Reynes Jacques; Clotet Bonaventura; Hui James; Salgo Miklos; DeMasi Ralph; Delehanty John
Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide.
The Journal of infectious diseases 2003;188(12):1827-33.
2003: Johnson Victoria A; Brun-Vézinet Françoise; Clotet Bonaventura; Conway Brian; D'Aquila Richard T; Demeter Lisa M; Kuritzkes Daniel R; Pillay Deenan; Schapiro Jonathan M; Telenti Amalio; Richman Douglas D;
Drug resistance mutations in HIV-1.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2003;11(6):215-21.
2003: Ruiz Lidia; Ribera Esteban; Bonjoch Anna; Romeu Joan; Martinez-Picado Javier; Paredes Roger; Díaz Marjorie; Marfil Silvia; Negredo Eugenia; García-Prado Julia; Tural Cristina; Sirera Guillem; Clotet Bonaventura
Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study.
The Journal of infectious diseases 2003;188(7):977-85.
2003: Clotet Bonaventura; van der Valk Marc; Negredo Eugenia; Reiss Peter
Impact of nevirapine on lipid metabolism.
Journal of acquired immune deficiency syndromes (1999) 2003;34 Suppl 1():S79-84.
2003: Laguna Fernando; Videla Sebastián; Jiménez-Mejías Manuel E; Sirera Guillem; Torre-Cisneros Julián; Ribera Esteban; Prados Dolores; Clotet Bonaventura; Sust Mariano; López-Vélez Rogelio; Alvar Jorge;
Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
The Journal of antimicrobial chemotherapy 2003;52(3):464-8.
2003: Mocroft Amanda; Ruiz Lidia; Reiss Peter; Ledergerber Bruno; Katlama Christine; Lazzarin Adriano; Goebel Frank-Detlef; Phillips Andrew N; Clotet Bonaventura; Lundgren Jens D;
Virological rebound after suppression on highly active antiretroviral therapy.
AIDS (London, England) 2003;17(12):1741-51.
2003: Weber Jan; Rangel Hector R; Chakraborty Bikram; Tadele Mahlet; Martinez Miguel A; Martinez-Picado Javier; Marotta Michael L; Mirza Muneer; Ruiz Lidia; Clotet Bonaventura; Wrin Terri; Petropoulos Christos J; Quiñones-Mateu Miguel E
A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy.
The Journal of general virology 2003;84(Pt 8):2217-28.
2003: Barretina J; Juncà J; Llano A; Gutiérrez A; Flores A; Blanco J; Clotet B; Esté J A
CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease.
Annals of hematology 2003;82(8):500-5.
2003: Fumaz Carmina R; Clotet Bonaventura
Assessment of changes in adherence and quality of life after the simplification of antiretroviral treatment.
IAPAC monthly 2003;9(7):145, 165.
2003: Armand-Ugón Mercedes; Gutiérrez Arantxa; Clotet Bonaventura; Esté José A
HIV-1 resistance to the gp41-dependent fusion inhibitor C-34.
Antiviral research 2003;59(2):137-42.
2003: Hirsch Martin S; Brun-Vézinet Françoise; Clotet Bonaventura; Conway Brian; Kuritzkes Daniel R; D'Aquila Richard T; Demeter Lisa M; Hammer Scott M; Johnson Victoria A; Loveday Clive; Mellors John W; Richman Douglas D;
Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2003;11(4):150-4.
2003: Martinez-Picado Javier; Negredo Eugènia; Ruiz Lidia; Shintani Ayumi; Fumaz Carmina R; Zala Carlos; Domingo Pere; Vilaró Josep; Llibre Josep M; Viciana Pompeyo; Hertogs Kurt; Boucher Charles; D'Aquila Richard T; Clotet Bonaventura;
Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial.
Annals of internal medicine 2003;139(2):81-9.
2003: Hirsch Martin S; Brun-Vézinet Françoise; Clotet Bonaventura; Conway Brian; Kuritzkes Daniel R; D'Aquila Richard T; Demeter Lisa M; Hammer Scott M; Johnson Victoria A; Loveday Clive; Mellors John W; Jacobsen Donna M; Richman Douglas D
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;37(1):113-28.
2003: D'Aquila Richard T; Schapiro Jonathan M; Brun-Vézinet Françoise; Clotet Bonaventura; Conway Brian; Demeter Lisa M; Grant Robert M; Johnson Victoria A; Kuritzkes Daniel R; Loveday Clive; Shafer Robert W; Richman Douglas D
Drug resistance mutations in HIV-1.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2003;11(3):92-6.
2003: Lazzarin Adriano; Clotet Bonaventura; Cooper David; Reynes Jacques; Arastéh Keikawus; Nelson Mark; Katlama Christine; Stellbrink Hans-Jürgen; Delfraissy Jean-François; Lange Joep; Huson Les; DeMasi Ralph; Wat Cynthia; Delehanty John; Drobnes Claude; Salgo Miklos;
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
The New England journal of medicine 2003;348(22):2186-95.
2003: Fagard Catherine; Oxenius Annette; Günthard Huldrych; Garcia Felipe; Le Braz Michelle; Mestre Gabriel; Battegay Manuel; Furrer Hansjakob; Vernazza Pietro; Bernasconi Enos; Telenti Amalio; Weber Rainer; Leduc Dominique; Yerly Sabine; Price David; Dawson Sara J; Klimkait Thomas; Perneger Thomas V; McLean Angela; Clotet Bonaventura; Gatell Jose M; Perrin Luc; Plana Montserrat; Phillips Rodney; Hirschel Bernard;
A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
Archives of internal medicine 2003;163(10):1220-6.
2003: Martinez Miguel Angel; Clotet Bonaventura
Genetic screen for monitoring hepatitis C virus NS3 serine protease activity.
Antimicrobial agents and chemotherapy 2003;47(5):1760-5.
2003: van Leeuwen Remko; Katlama Christine; Murphy Robert L; Squires Kathleen; Gatell José; Horban Andrej; Clotet Bonaventura; Staszewski Shlomo; van Eeden Arne; Clumeck Nathan; Moroni Mauro; Pavia Andrew T; Schmidt Reinhold E; Gonzalez-Lahoz Juan; Montaner Julio; Antunes Francisco; Gulick Robert; Bánhegyi Dénes; van der Valk Marc; Reiss Peter; van Weert Liesbeth; van Leth Frank; Johnson Victoria A; Sommadossi Jean-Pierre; Lange Joep M
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients.
AIDS (London, England) 2003;17(7):987-99.
2003: Fuster Daniel; Clotet Bonaventura
Chronic HCV infection in HIV-positive patients: a new challenge.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 2003;2(2):56-8.
2003: Barretina Jordi; Blanco Julià; Armand-Ugón Mercedes; Gutiérrez Arantxa; Clotet Bonaventura; Esté José A
Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death.
Antiviral therapy 2003;8(2):155-61.
2003: Cozzi-Lepri Alessandro; Phillips Andrew N; Miller Veronica; Katlama Christine; Ledergerber Bruno; Vella Stefano; Weber Jonathan; Bruun Johan N; Kirk Ole; Clotet Bonaventura; Lundgrens Jens D
Changes in viral load in people with virological failure who remain on the same HAART regimen.
Antiviral therapy 2003;8(2):127-36.
2003: Llano Anuska; Barretina Jordi; Gutiérrez Arantxa; Clotet Bonaventura; Esté José A
Interleukin-7-dependent production of RANTES that correlates with human immunodeficiency virus disease progression.
Journal of virology 2003;77(7):4389-95.
2003: Tural C; Fuster D; Tor J; Ojanguren I; Sirera G; Ballesteros A; Lasanta J A J; Planas R; Rey-Joly C; Clotet B
Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients.
Journal of viral hepatitis 2003;10(2):118-25.
2003: Tàpia Natàlia; Franco Sandra; Puig-Basagoiti Francesc; Menéndez Clara; Alonso Pedro Luis; Mshinda Hassan; Clotet Bonaventura; Saiz Juan Carlos; Martínez Miguel Angel
Influence of human immunodeficiency virus type 1 subtype on mother-to-child transmission.
The Journal of general virology 2003;84(Pt 3):607-13.
2003: Armand-Ugón Mercedes; Quiñones-Mateu Miguel E; Gutiérez Arantxa; Barretina Jordi; Blanco Julià; Schols Dominique; De Clercq Erik; Clotet Bonaventura; Esté José A
Reduced fitness of HIV-1 resistant to CXCR4 antagonists.
Antiviral therapy 2003;8(1):1-8.
2003: Clotet Bonaventura; Negredo Eugènia
HIV protease inhibitors and dyslipidemia.
AIDS reviews 2003;5(1):19-24.
2003: Blanco Julià; Barretina Jordi; Ferri Karine F; Jacotot Etienne; Gutiérrez Arantxa; Armand-Ugón Mercedes; Cabrera Cecilia; Kroemer Guido; Clotet Bonaventura; Esté José A
Cell-surface-expressed HIV-1 envelope induces the death of CD4 T cells during GP41-mediated hemifusion-like events.
Virology 2003;305(2):318-29.
2003: Paredes Roger; Clotet Bonaventura
New antiretroviral drugs and approaches to HIV treatment.
AIDS (London, England) 2003;17 Suppl 4():S85-96.
2002: Martínez Miguel Angel; Clotet Bonaventura; Esté José A
RNA interference of HIV replication.
Trends in immunology 2002;23(12):559-61.
2002: Martínez Miguel A; Gutiérrez Arantxa; Armand-Ugón Mercedes; Blanco Julià; Parera Mariona; Gómez Jordi; Clotet Bonaventura; Esté José A
Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication.
AIDS (London, England) 2002;16(18):2385-90.
2002: Martinez-Picado Javier; Frost Simon D W; Izquierdo Nuria; Morales-Lopetegi K; Marfil Silvia; Puig Teresa; Cabrera Cecilia; Clotet Bonaventura; Ruiz Lidia
Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individuals.
Journal of virology 2002;76(23):12344-8.
2002: Egea J M; Muga R; Sirera G; Clotet B; Tor J; Ardèvol M; Rey-Joly C; Muñoz A
Initiation, changes in use and effectiveness of highly active anti-retroviral therapy in a cohort of injecting drug users.
Epidemiology and infection 2002;129(2):325-33.
2002: Gallego Oscar; Ruíz Lidia; Vallejo Alex; Clotet Bonaventura; Leal Manuel; Soriano Vincent
Rate of virological treatment failure and frequencies of drug resistance genotypes among human immunodeficiency virus-positive subjects on antiretroviral therapy in Spain.
Journal of clinical microbiology 2002;40(10):3865-6.
2002: Quiñones-Mateu Miguel E; Tadele Mahlet; Parera Mariona; Mas Antonio; Weber Jan; Rangel Héctor R; Chakraborty Bikram; Clotet Bonaventura; Domingo Esteban; Menéndez-Arias Luis; Martínez Miguel A
Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation.
Journal of virology 2002;76(20):10546-52.
2002: Cabana Marta; Fernàndez Guerau; Parera Mariona; Clotet Bonaventura; Martínez Miguel Angel
Catalytic efficiency and phenotype of HIV-1 proteases encoding single critical resistance substitutions.
Virology 2002;300(1):71-8.
2002: Ait-Khaled Mounir; Stone Chris; Amphlett Gillian; Clotet Bonaventura; Staszewski Schlomo; Katlama Christine; Tisdale Margaret;
M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine.
AIDS (London, England) 2002;16(12):1686-9.
2002: García Felipe; Clotet Bonaventura; Moreno Santiago; López Bernaldo De Quirós Juan Carlos; Gatell José M
[Treatment interruptions in clinical practice]
Enfermedades infecciosas y microbiologia clinica 2002;20 Suppl 2():68-73.
2002: Clotet Bonaventura; Ruiz Lidia; Martinez-Picado Javier; Negredo Eugènia; Hill Andrew; Popescu Matei
Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts.
HIV clinical trials 2002;3(4):316-23.
2002: Miller Veronica; Phillips Andrew N; Clotet Bonaventura; Mocroft Amanda; Ledergerber Bruno; Kirk Ole; Ormaasen Vidar; Gargalianos-Kakolyris Panagiotis; Vella Stefano; Lundgren Jens D
Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts.
The Journal of infectious diseases 2002;186(2):189-97.
2002: Negredo Eugenia; Ribalta Josep; Paredes Roger; Ferré Raimón; Sirera Guillem; Ruiz Lidia; Salazar Juliana; Reiss Peter; Masana Lluís; Clotet Bonaventura
Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.
AIDS (London, England) 2002;16(10):1383-9.
2002: Prado Julia G; Wrin Terri; Beauchaine Jeff; Ruiz Lidia; Petropoulos Christos J; Frost Simon D W; Clotet Bonaventura; D'Aquila Richard T; Martinez-Picado Javier
Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.
AIDS (London, England) 2002;16(7):1009-17.
2002: Martinez-Picado Javier; Morales-Lopetegi Kristina; Wrin Terri; Prado Julia G; Frost Simon D W; Petropoulos Christos J; Clotet Bonaventura; Ruiz Lidia
Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions.
AIDS (London, England) 2002;16(6):895-9.
2002: Mocroft A; Phillips A N; Friis-Møller N; Colebunders R; Johnson A M; Hirschel B; Saint-Marc T; Staub T; Clotet B; Lundgren J D;
Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study.
Antiviral therapy 2002;7(1):21-30.
2002: Fumaz Carmina R; Tuldrà Albert; Ferrer Ma José; Paredes Roger; Bonjoch Anna; Jou Toni; Negredo Eugènia; Romeu Joan; Sirera Guillem; Tural Cristina; Clotet Bonaventura
Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens.
Journal of acquired immune deficiency syndromes (1999) 2002;29(3):244-53.
2002: Negredo Eugenia; Cruz Luís; Paredes Roger; Ruiz Lidia; Fumaz Carmina R; Bonjoch Anna; Gel Silvia; Tuldrà Albert; Balagué Montserrat; Johnston Susan; Arnó Albert; Jou Antoni; Tural Cristina; Sirera Guillem; Romeu Joan; Clotet Bonaventura
Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002;34(4):504-10.
2002: Frost Simon D W; Martinez-Picado Javier; Ruiz Lidia; Clotet Bonaventura; Brown Andrew J Leigh
Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection.
Journal of virology 2002;76(3):968-79.
2002: Paredes Roger; López Benaldo de Quirós Juan Carlos; Fernández-Cruz Eduardo; Clotet Bonaventura; Lane H Clifford
The potential role of interleukin-2 in patients with HIV infection.
AIDS reviews 2002;4(1):36-40.
2002: Tural Cristina; Ruiz Lidia; Holtzer Christopher; Schapiro Jonathan; Viciana Pompeyo; González Juan; Domingo Pere; Boucher Charles; Rey-Joly C; Clotet Bonaventura;
Clinical utility of HIV-1 genotyping and expert advice: the Havana trial.
AIDS (London, England) 2002;16(2):209-18.
2002: Blanco Julià; Barretina Jordi; Gutiérrez Arantxa; Armand-Ugón Mercedes; Cabrera Cecilia; Clotet Bonaventura; Esté José A
Preferential attachment of HIV particles to activated and CD45RO+CD4+ T cells.
AIDS research and human retroviruses 2002;18(1):27-38.
2002: Cabrera Cecilia; Gutiérrez Arantxa; Barretina Jordi; Blanco Julià; Litovchick Alexander; Lapidot Aviva; Clotet Bonaventura; Esté José A
Anti-HIV activity of a novel aminoglycoside-arginine conjugate.
Antiviral research 2002;53(1):1-8.
2001: van der Valk M; Kastelein J J; Murphy R L; van Leth F; Katlama C; Horban A; Glesby M; Behrens G; Clotet B; Stellato R K; Molhuizen H O; Reiss P;
Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile.
AIDS (London, England) 2001;15(18):2407-14.
2001: Phillips A N; Pradier C; Lazzarin A; Clotet B; Goebel F D; Hermans P; Antunes F; Ledergerber B; Kirk O; Lundgren J D;
Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients.
AIDS (London, England) 2001;15(18):2385-95.
2001: Llano A; Barretina J; Gutiérrez A; Blanco J; Cabrera C; Clotet B; Esté J A
Interleukin-7 in plasma correlates with CD4 T-cell depletion and may be associated with emergence of syncytium-inducing variants in human immunodeficiency virus type 1-positive individuals.
Journal of virology 2001;75(21):10319-25.
2001: Tuldrà A; Fumaz C R; Ferrer M J; Paredes R; Romeu J; Ruiz L; Bayés R; Clotet B
Psychological impact of structured treatment interruptions in patients with prolonged undetectable HIV-1 viral loads.
AIDS (London, England) 2001;15(14):1904-6.
2001: Llano A; Barretina J; Blanco J; Gutiérrez A; Clotet B; Esté J A
Stromal-cell-derived factor 1 prevents the emergence of the syncytium-inducing phenotype of HIV-1 in vivo.
AIDS (London, England) 2001;15(14):1890-2.
2001: Ruiz L; Negredo E; Domingo P; Paredes R; Francia E; Balagué M; Gel S; Bonjoch A; Fumaz C R; Johnston S; Romeu J; Lange J; Clotet B;
Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.
Journal of acquired immune deficiency syndromes (1999) 2001;27(3):229-36.
2001: Blanco J; Barretina J; Cabrera C; Gutiérrez A; Clotet B; Esté J A
CD4(+) and CD8(+) T cell death during human immunodeficiency virus infection in vitro.
Virology 2001;285(2):356-65.
2001: Ruiz L; Carcelain G; Martínez-Picado J; Frost S; Marfil S; Paredes R; Romeu J; Ferrer E; Morales-Lopetegi K; Autran B; Clotet B
HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection.
AIDS (London, England) 2001;15(9):F19-27.
2001: Kirk O; Mocroft A; Pradier C; Bruun J N; Hemmer R; Clotet B; Miller V; Viard J P; Phillips A N; Lundgren J D;
Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir.
AIDS (London, England) 2001;15(8):999-1008.
2001: Casado E; Olivé A; Holgado S; Perez-Andres R; Romeu J; Lorenzo J C; Clotet B; Tena X
Musculoskeletal manifestations in patients positive for human immunodeficiency virus: correlation with CD4 count.
The Journal of rheumatology 2001;28(4):802-4.
2001: Vandamme A M; Houyez F; Bànhegyi D; Clotet B; De Schrijver G; De Smet K A; Hall W W; Harrigan R; Hellmann N; Hertogs K; Holtzer C; Larder B; Pillay D; Race E; Schmit J C; Schuurman R; Schulse E; Sönnerborg A; Miller V
Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up.
Antiviral therapy 2001;6(1):21-39.
2001: Ibáñez A; Clotet B; Martínez M A
Absence of genetic diversity reduction in the HIV-1 integrated proviral LTR sequence population during successful combination therapy.
Virology 2001;282(1):1-5.
2001: Gatell J M; Blanco J L; Alcamí J; Antela A; Arrizabalaga J; Casado J L; Clotet B; Delgado R; Erice A; Guerra L; Guerrero A; Iribarren J A; Leal M; López J C; Menéndez-Arias L; Miró J M; Moreno S; Pérez J L; Pumarola T; Rubio R; Ruiz L; Santamaría J M; Soriano V; Telenti A; Viciana P
[GESIDA Consensus document on the use of resistance studies in clinical practice]
Enfermedades infecciosas y microbiología clínica 2001;19(Monografico):53-60.
2001: Antela A; Iribarren J A; Clotet B; Guerra L
[Consensus documents and clinical guidelines on resistance to antiretroviral agents]
Enfermedades infecciosas y microbiología clínica 2001;19(Monografico):47-52.
2001: Katlama C; Clotet B; Plettenberg A; Jost J; Arasteh K; Bernasconi E; Jeantils V; Cutrell A; Stone C; Purdon S;
Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial.
HIV medicine 2001;2(1):27-34.
2000: Tuldrà A; Fumaz C R; Ferrer M J; Bayés R; Arnó A; Balagué M; Bonjoch A; Jou A; Negredo E; Paredes R; Ruiz L; Romeu J; Sirera G; Tural C; Burger D; Clotet B
Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999) 2000;25(3):221-8.
2000: Miró J M; Antela A; Arrizabalaga J; Clotet B; Gatell J M; Guerra L; Antonio Iribarren J; Laguna F; Moreno S; Parras F; Rubio R; Santamaría J M; Viciana P;
[Recommendations of GESIDA (Grupo de Estudio de SIDA)/National Plan on AIDS with respect to the anti-retroviral treatment in adult patients infected with the human immunodeficiency virus in the year 2000 (II)]
Enfermedades infecciosas y microbiología clínica 2000;18(8):396-412.
2000: García F; Alonso M M; Romeu J; Knobel H; Arrizabalaga J; Ferrer E; Dalmau D; Ruiz I; Vidal F; Frances A; Segura F; Gomez-Sirvent J L; Cruceta A; Clotet B; Pumarola T; Gallart T; O'Brien W A; Miró J M; Gatell J M
Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.
Journal of acquired immune deficiency syndromes (1999) 2000;25(1):26-35.
2000: Miró J M; Antela A; Arrizabalaga J; Clotet B; Gatell J M; Guerra L; Iribarren J A; Laguna F; Moreno S; Parras F; Rubio R; Santamaría J M; Viciana P
[Recommendation of GESIDA (AIDS Study Group)/National Plan on AIDS with respect to the anti-retroviral treatment in adult patients infected with the human immunodeficiency virus in the year 2000 (I)]
Enfermedades infecciosas y microbiología clínica 2000;18(7):329-51.
2000: Van Vaerenbergh K; Van Laethem K; Albert J; Boucher C A; Clotet B; Floridia M; Gerstoft J; Hejdeman B; Nielsen C; Pannecouque C; Perrin L; Pirillo M F; Ruiz L; Schmit J C; Schneider F; Schoolmeester A; Schuurman R; Stellbrink H J; Stuyver L; Van Lunzen J; Van Remoortel B; Van Wijngaerden E; Vella S; Witvrouw M; Yerly S; De Clercq E; Destmyer J; Vandamme A M
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues.
Antimicrobial agents and chemotherapy 2000;44(8):2109-17.
2000: Mocroft A; Miller V; Chiesi A; Blaxhult A; Katlama C; Clotet B; Barton S; Lundgren J D
Virological failure among patients on HAART from across Europe: results from the EuroSIDA study.
Antiviral therapy 2000;5(2):107-12.
2000: Van Laethem K; Schmit J C; Pelemans H; Balzarini J; Witvrouw M; Pérez-Pérez M J; Camarasa M J; Esnouf R M; Aquaro S; Cenci A; Perno C F; Hermans P; Sprecher S; Ruiz L; Clotet B; Van Wijngaerden E; Van Ranst M; Desmyter J; De Clercq E; Vandamme A M
Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients.
AIDS research and human retroviruses 2000;16(9):825-33.
2000: Giménez-Barcons M; Sánchez-Fueyo A; Ampurdanés S; Puig-Basagoiti F; Guilera M; Ibáñez A; Clotet B; Martínez M A; Rodés J; Saiz J C; Sánchez-Tapias J M
Genetic evolution of GB virus C/hepatitis G virus (GBV-C/HGV) under interferon pressure.
Antiviral research 2000;46(2):157-70.
2000: Katlama C; Clotet B; Plettenberg A; Jost J; Arasteh K; Bernasconi E; Jeantils V; Cutrell A; Stone C; Ait-Khaled M; Purdon S
The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team.
AIDS (London, England) 2000;14(7):781-9.
2000: Hirsch M S; Brun-Vézinet F; D'Aquila R T; Hammer S M; Johnson V A; Kuritzkes D R; Loveday C; Mellors J W; Clotet B; Conway B; Demeter L M; Vella S; Jacobsen D M; Richman D D
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.
JAMA : the journal of the American Medical Association 2000;283(18):2417-26.
2000: Cabrera C; Gutiérrez A; Blanco J; Barretina J; Litovchick A; Lapidot A; Evdokimov A G; Clotet B; Esté J A
Anti-human immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infection.
AIDS research and human retroviruses 2000;16(7):627-34.
2000: Martínez M A; Cabana M; Parera M; Gutierrez A; Esté J A; Clotet B
A bacteriophage lambda-based genetic screen for characterization of the activity and phenotype of the human immunodeficiency virus type 1 protease.
Antimicrobial agents and chemotherapy 2000;44(5):1132-9.
2000: Puig T; Pérez-Olmeda M; Rubio A; Ruiz L; Briones C; Franco J M; Gómez-Cano M; Stuyver L; Zamora L; Alvarez C; Leal M; Clotet B; Soriano V
Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group.
AIDS (London, England) 2000;14(6):727-32.
2000: Paredes R; Mocroft A; Kirk O; Lazzarin A; Barton S E; van Lunzen J; Katzenstein T L; Antunes F; Lundgren J D; Clotet B
Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.
Archives of internal medicine 2000;160(8):1123-32.
2000: Van Vaerenbergh K; Van Laethem K; Van Wijngaerden E; Schmit J C; Schneider F; Ruiz L; Clotet B; Verhofstede C; Van Wanzeele F; Muyldermans G; Simons P; Stuyver L; Hermans P; Evans C; De Clercq E; Desmyter J; Vandamme A M
Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy.
AIDS research and human retroviruses 2000;16(6):529-37.
2000: Van Laethem K; Witvrouw M; Balzarini J; Schmit J C; Sprecher S; Hermans P; Leal M; Harrer T; Ruiz L; Clotet B; Van Ranst M; Desmyter J; De Clercq E; Vandamme A M
Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir.
AIDS (London, England) 2000;14(4):469-71.
2000: Ruiz L; Martinez-Picado J; Romeu J; Paredes R; Zayat M K; Marfil S; Negredo E; Sirera G; Tural C; Clotet B
Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.
AIDS (London, England) 2000;14(4):397-403.
2000: Casado J L; Hertogs K; Ruiz L; Dronda F; Van Cauwenberge A; Arnó A; Garcia-Arata I; Bloor S; Bonjoch A; Blazquez J; Clotet B; Larder B
Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.
AIDS (London, England) 2000;14(2):F1-7.
2000: Puig-Basagoiti F; Cabana M; Guilera M; Giménez-Barcons M; Sirera G; Tural C; Clotet B; Sánchez-Tapias J M; Rodés J; Saiz J C; Martínez M A
Prevalence and route of transmission of infection with a novel DNA virus (TTV), hepatitis C virus, and hepatitis G virus in patients infected with HIV.
Journal of acquired immune deficiency syndromes (1999) 2000;23(1):89-94.
2000: Ibáñez A; Clotet B; Martínez M A
Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies.
The Journal of general virology 2000;81(Pt 1):85-95.
2000: Blanco J; Barretina J; Henson G; Bridger G; De Clercq E; Clotet B; Esté J A
The CXCR4 antagonist AMD3100 efficiently inhibits cell-surface-expressed human immunodeficiency virus type 1 envelope-induced apoptosis.
Antimicrobial agents and chemotherapy 2000;44(1):51-6.
1999: García F; Romeu J; Grau I; Sambeat M A; Dalmau D; Knobel H; Gomez-Sirvent J L; Arrizabalaga J; Cruceta A; Clotet B G; Podzamczer D; Pumarola T; Gallart T; O'Brien W A; Miró J M; Gatell J M
A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
AIDS (London, England) 1999;13(17):2377-88.
1999: Cabana M; Clotet B; Martínez M A
Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors.
Journal of medical virology 1999;59(4):480-90.
1999: Cabrera C; Witvrouw M; Gutiérrez A; Clotet B; Kuipers M E; Swart P J; Meijer D K; Desmyter J; De Clercq E; Esté J A
Resistance of the human immunodeficiency virus to the inhibitory action of negatively charged albumins on virus binding to CD4.
AIDS research and human retroviruses 1999;15(17):1535-43.
1999: Paredes R; Puig T; Arnó A; Negredo E; Balagué M; Bonjoch A; Jou A; Tuldrà A; Tural C; Sirera G; Veny A; Romeu J; Ruiz L; Clotet B
High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response.
Journal of acquired immune deficiency syndromes (1999) 1999;22(2):132-8.
1999: Esté J A; Cabrera C; Blanco J; Gutierrez A; Bridger G; Henson G; Clotet B; Schols D; De Clercq E
Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4.
Journal of virology 1999;73(7):5577-85.
1999: Arnó A; Ruiz L; Juan M; Jou A; Balagué M; Zayat M K; Marfil S; Martínez-Picado J; Martínez M A; Romeu J; Pujol-Borrell R; Lane C; Clotet B
Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load.
The Journal of infectious diseases 1999;180(1):56-60.
1999: Ibáñez A; Puig T; Elias J; Clotet B; Ruiz L; Martínez M A
Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients.
AIDS (London, England) 1999;13(9):1045-9.
1999: Tuldrà A; Ferrer M J; Fumaz C R; Bayés R; Paredes R; Burger D M; Clotet B
Monitoring adherence to HIV therapy.
Archives of internal medicine 1999;159(12):1376-7.
1999: Blanco J; Jacotot E; Cabrera C; Cardona A; Clotet B; De Clercq E; Esté J A
The implication of the chemokine receptor CXCR4 in HIV-1 envelope protein-induced apoptosis is independent of the G protein-mediated signalling.
AIDS (London, England) 1999;13(8):909-17.
1999: Blanco J; Cabrera C; Jou A; Ruiz L; Clotet B; Esté J A
Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy.
AIDS (London, England) 1999;13(5):547-55.
1999: Martínez M A; Cabana M; Ibáñez A; Clotet B; Arnó A; Ruiz L
Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia.
Virology 1999;256(2):180-7.
1999: Ruiz L; van Lunzen J; Arno A; Stellbrink H J; Schneider C; Rull M; Castellà E; Ojanguren I; Richman D D; Clotet B; Tenner-Racz K; Racz P
Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue.
AIDS (London, England) 1999;13(1):F1-8.
1999: Esté J A; Cabrera C; De Clercq E; Struyf S; Van Damme J; Bridger G; Skerlj R T; Abrams M J; Henson G; Gutierrez A; Clotet B; Schols D
Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor.
Molecular pharmacology 1999;55(1):67-73.
1999: Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz C R; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas J R; Ruiz L; Clotet B
Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
Antiviral therapy 1999;4 Suppl 3():23-8.
1999: Gómez-Cano M; Rubio A; Ruiz L; Pérez-Olmeda M; Leal M; Clotet B; Soriano V
Efficiency of drug resistance genotypic tests in specimens with low HIV viral load.
Antiviral therapy 1999;4(2):123-4.
1999: Rubio A; Gómez-Cano M; Puig T; Leal M; Pérez-Olmeda M; Ruiz L; Clotet B; Rey C; Zamora L; Xaus N; Soriano V
Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load.
Antiviral therapy 1999;4(1):45-9.
1998: Moreno S; Arrizabalaga J; Gatell J M; Clotet B; Aguirrebengoa K; Antela A; Iribarren J A; Laguna F; Miró J M; Ocaña I; Rubio R; Viciana P; Podzamczer D
[Recommendations for antiretroviral treatment in 1998. AIDS Working Group of the Spanish Society for Infectious Diseases and Clinical Microbiology (SEIMC)]
Enfermedades infecciosas y microbiología clínica 1998;16(8):374-6.
1998: Schmit J C; Van Laethem K; Ruiz L; Hermans P; Sprecher S; Sönnerborg A; Leal M; Harrer T; Clotet B; Arendt V; Lissen E; Witvrouw M; Desmyter J; De Clercq E; Vandamme A M
Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries.
AIDS (London, England) 1998;12(15):2007-15.
1998: Este J A; Clotet B
HIV phenotype & genotype data highlights Lake Maggiore meeting.
Journal of the International Association of Physicians in AIDS Care 1998;4(9):60-3.
1998: Ruiz L; Nijhuis M; Boucher C; Puig T; Bonjoch A; Martínez-Picado J; Marfil S; de Jong D; Burger D; Arnó A; Balagué M; Clotet B
Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1998;19(1):19-28.
1998: Ibáñez A; Giménez-Barcons M; Tajahuerce A; Tural C; Sirera G; Clotet B; Sánchez-Tapias J M; Rodés J; Martínez M A; Saiz J C
Prevalence and genotypes of GB virus C/hepatitis G virus (GBV-C/HGV) and hepatitis C virus among patients infected with human immunodeficiency virus: evidence of GBV-C/HGV sexual transmission.
Journal of medical virology 1998;55(4):293-9.
1998: Vidal C; García F; Romeu J; Ruiz L; Miró J M; Cruceta A; Soriano A; Pumarola T; Clotet B; Gatell J M
Lack of evidence of a stable viral load set-point in early stage asymptomatic patients with chronic HIV-1 infection.
AIDS (London, England) 1998;12(11):1285-9.
1998: Schmit J C; Ruiz L; Stuyver L; Van Laethem K; Vanderlinden I; Puig T; Rossau R; Desmyter J; De Clercq E; Clotet B; Vandamme A M
Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations.
Journal of virological methods 1998;73(1):77-82.
1998: Romeu J; Balagué M; Ruiz L; Marfil S; Puig T; Arnó A; Veny A; Tural C; Sirera G; Clotet B
[Value of HIV-1 viral load and CD4 lymphocyte count as determinants of progression to AIDS and survival]
Medicina clínica 1998;110(20):761-7.
1998: Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda J A; Zamora L; Xaus N; Clotet B; Leal M
Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
AIDS (London, England) 1998;12(9):1015-20.
1998: Hirsch M S; Conway B; D'Aquila R T; Johnson V A; Brun-Vézinet F; Clotet B; Demeter L M; Hammer S M; Jacobsen D M; Kuritzkes D R; Loveday C; Mellors J W; Vella S; Richman D D
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.
JAMA : the journal of the American Medical Association 1998;279(24):1984-91.
1998: Arnó A; Ruiz L; Juan M; Zayat M K; Puig T; Balagué M; Romeu J; Pujol R; O'Brien W A; Clotet B
Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years.
AIDS (London, England) 1998;12(7):697-704.
1998: Tural C; Romeu J; Sirera G; Andreu D; Conejero M; Ruiz S; Jou A; Bonjoch A; Ruiz L; Arnó A; Clotet B
Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients.
The Journal of infectious diseases 1998;177(4):1080-3.
1998: Phillips A N; Katlama C; Barton S; Vella S; Blaxhult A; Clotet B; Goebel F D; Hirschel B; Pedersen C; Lundgren J D
Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1998;17(3):239-44.
1998: Moreno S; Arrizabalaga J; Gatell J M; Clotet B; Aguirrebengoa K; Antela A; Iribarren J A; Laguna F; Miró J M; Ocaña I; Rubio R; Viciana P; Podzamczer D
[Recommendations on antiretroviral treatment. The AIDS Study Group of the Spanish Society of Infectious Diseases and Clinical Microbiology]
Medicina clínica 1998;110(3):109-16.
1997: Paredes R; Laguna F; Clotet B
Leishmaniasis in HIV-infected persons: a review.
Journal of the International Association of Physicians in AIDS Care 1997;3(6):22-39.
1997: Ibáñez A; Peraire J; Arnó A; Gutiérrez C; Cervantes M; Colomer J; Villalonga C; Camafort M; Ruiz L; Balaguer M; Vidal F; Richart C; Clotet B
Immunological and virological activity of zalcitabine and zidovudine in combination in HIV-positive people with CD4 cell counts of between 200-500 cells/mm3.
Antiviral therapy 1997;2(2):105-11.
1996: Ruiz L; Romeu J; Ibáñez A; Cabrera C; Puig T; Morales M A; Sirera G; Clotet B
Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
Antiviral therapy 1996;1(4):220-4.
1996: Ruiz L; Romeu J; Martínez-Picado J; Schmit J C; Vandamme A M; Balagué M; Cabrera C; Puig T; Tural C; Segura A; Sirera G; De Clercq E; Clotet B
Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC.
AIDS (London, England) 1996;10(14):F61-6.
1996: Ruiz L; Romeu J; Clotet B; Balagué M; Cabrera C; Sirera G; Ibáñez A; Martínez-Picado J; Raventós A; Tural C; Segura A; Foz M
Quantitative HIV-1 RNA as a marker of clinical stability and survival in a cohort of 302 patients with a mean CD4 cell count of 300 x 10(6)/l.
AIDS (London, England) 1996;10(11):F39-44.
1996: Clotet B; Ruiz L; Cabrera C; Ibáñez A; Cañadas M P; Sirera G; Romeu J; Vila J
Short-term anti-HIV activity of the combination of didanosine and hydroxyurea.
Antiviral therapy 1996;1(3):189-93.
1996: Schmit J C; Ruiz L; Clotet B; Raventos A; Tor J; Leonard J; Desmyter J; De Clercq E; Vandamme A M
Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538).
AIDS (London, England) 1996;10(9):995-9.
1996: Bayés B; Romeu J; Vaquero M; Ribera M; Navarro J T; Rosell A; Sirera G; Clotet B
[Disseminated histoplasmosis and AIDS. Report of 4 cases]
Medicina clínica 1996;106(18):700-3.
1996: Estrada O; Romeu J; Giménez G; Raventós A; Sirera G; Clotet B
[Bronchogenic carcinoma in patients with human immunodeficiency virus infection]
Medicina clínica 1996;106(17):661-4.
1991: Romeu J; Millà F; Batlle M; Sirera G; Ferrandiz C; Carreres A; Condom M J; Clotet B
Visceral leishmaniasis involving lung and a cutaneous Kaposi's sarcoma lesion.
AIDS (London, England) 1991;5(10):1272.
1991: Clotet B; Sirera G; Romeu J; Gimeno J M; Jou A; Condom M J; Tor J; Foz M
Twice-weekly dapsone-pyrimethamine for preventing PCP and cerebral toxoplasmosis.
AIDS (London, England) 1991;5(5):601-2.
1990: Tor J; Llibre J M; Carbonell M; Muga R; Ribera A; Soriano V; Clotet B; Sabriá M; Foz M
Sexual transmission of hepatitis C virus and its relation with hepatitis B virus and HIV.
BMJ (Clinical research ed.) 1990;301(6761):1130-3.
1990: Sirera G; Millá F; Condom M J; Clotet B
[Asymptomatic visceral leishmaniasis in a patient with acquired immunodeficiency syndrome]
Medicina clínica 1990;94(5):196.
1989: Condom M J; Clotet B; Sirera G; Milla F; Foz M
Asymptomatic leishmaniasis in the acquired immunodeficiency syndrome (AIDS)
Annals of internal medicine 1989;111(9):767-8.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Bonaventura Clotet

Research Profile (preview)

Disorders

Living Beings

Chemicals & Drugs

Procedures

Concepts & Ideas

Physiology

Anatomy

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Bonaventura Clotet (preview)

All Publications